Quercetin and Chlorogenic Acid Mitigate DSS-Induced Changes in Expression of Select Pro-Inflammatory Cytokines and Short Chain Fatty Acid Transporter Genes by Piefer, Leigh
 QUERCETIN AND CHLOROGENIC ACID MITIGATE DSS-INDUCED 
CHANGES IN EXPRESSION OF SELECT PRO-INFLAMMATORY  
CYTOKINES AND SHORT CHAIN FATTY ACID TRANSPORTER GENES 
 
 
 
 
 
 
A Thesis  
by 
LEIGH ANN PIEFER 
 
 
 
 
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
 
MASTER OF SCIENCE 
 
 
 
 
 
August 2012 
 
 
 
 
 
Major Subject: Nutrition 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quercetin and Chlorogenic Acid Mitigate DSS-Induced Changes in Expression of Select 
Pro-Inflammatory Cytokines and Short Chain Fatty Acid Transporter Genes 
Copyright 2012 Leigh Ann Piefer 
 QUERCETIN AND CHLOROGENIC ACID MITIGATE DSS-INDUCED 
CHANGES IN EXPRESSION OF SELECT PRO-INFLAMMATORY  
CYTOKINES AND SHORT CHAIN FATTY ACID TRANSPORTER GENES 
 
 
 
 
A Thesis 
by 
LEIGH ANN PIEFER 
 
 
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
 
MASTER OF SCIENCE 
 
 
 
Approved by: 
Chair of Committee,   Nancy D. Turner 
Committee Members,  Clinton D. Allred 
    David H. Byrne 
Interdisciplinary Faculty   
Chair,     Rosemary Walzem 
 
 
 
 
August 2012 
 
 
 
Major Subject: Nutrition
 iii 
ABSTRACT 
 
Quercetin and Chlorogenic Acid Mitigate DSS-Induced Changes in Expression of Select 
Pro-Inflammatory Cytokines and Short Chain Fatty Acid Transporter Genes.        
(August 2012) 
Leigh Ann Piefer, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Nancy D. Turner 
 
 Quercetin (Q) and chlorogenic acid (CA), two bioactive compounds found in 
stonefruits, may protect against inflammation and cancer because of anti-cancer, anti-
oxidant, and anti-inflammatory properties.  Since these compounds reach the colon 
undigested, they affect the luminal environment before they are metabolized by the 
microbiota and transported into epithelial cells.  We hypothesized that Q and CA may 
suppress expression of pro-inflammatory molecules, alter the luminal environment, and 
alter the cell cycle, thereby protecting against injury/colitis.  To test this hypothesis, 63 
male weanling rats were given one of three diets (basal, 0.45% Q, 0.05% CA).  After 3 
wk of acclimation, colitis was induced in 11 rats/diet [3% dextran sodium sulfate (DSS), 
48 h, 3 treatments, 2 wk separation] and 10 rats/diet served as control (0% DSS).  All 
rats were terminated at wk 9.  Measurements included: fecal moisture content, fecal 
short chain fatty acid (SCFA) concentrations (gas chromatography), epithelial injury and 
inflammation in the distal colon, proliferation (PCNA), and NF-κB activity (ELISA 
method) and gene expression (real time RT-PCR) in mucosal scrapings. Fecal moisture 
 iv 
content was significantly increased by DSS exposure (p<0.05), and never returned to 
control levels. Fecal SCFA concentrations also increased with DSS (acetate, p<0.05; 
butyrate, p<0.05).  Increased SCFA concentrations could indicate decreased SCFA 
uptake.  Experimental diets were able to mitigate DSS-induced decreases in SLC5A8 
(SCFA transporter) expression.  DSS significantly increased injury (p<0.0001) and 
inflammation (p<0.01) scores. Compared to the basal diet, CA decreased NF-κB activity 
in DSS-treated rats (p<0.05). Q and CA may maintain healthy regulation of NF-κB 
through maintaining expression levels of IκΒα and Tollip, molecules that inhibit NF-κB 
activation.  Q and CA mitigated DSS-induced increases in pro-inflammatory cytokine 
expression, specifically IL-1.  Q enhanced expression of injury-repair molecule FGF-2 
(p<0.01), but neither diet nor DSS treatment altered proliferation.  Although Q and CA 
did not protect against DSS-induced increases in injury and inflammation scores or fecal 
SCFA concentrations, their influence on expression of injury repair molecules, pro-
inflammatory cytokines, SCFA transport proteins, and NF-κB inhibitory molecules 
suggests beneficial influences on major pathways involved in DSS-induced 
injury/inflammation.  The combined benefit of these compounds could have 
additive/synergistic effects and, therefore, deserve further examination. 
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NOMENCLATURE 
  
CD  crohn’s disease 
COX  cyclooxygenase 
CRC  colorectal cancer  
ddH2O  distilled deionized water 
DSS  dextran sodium sulfate 
ELISA  enzyme-linked immunosorbent assay 
EtOH  ethanol 
FGF  fibroblast growth factor 
GI  gastrointestinal  
IBD  inflammatory bowel disease 
IΚΚ  NF-κB kinase 
IL  interleukin 
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LPS  lipopolysaccharide 
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MCT-1 monocarboxylate transporter-1 
MyD88 myeloid differentiation factor-88 
NF-κB  nuclear transcription factor kappa B 
PBS  phosphate buffered solution 
PFA  paraformaldehyde 
RT-PCR reverse transcriptase polymerase chain reaction 
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RIP  receptor interacting protein 
SEM  standard error of the mean 
SLC5A8 sodium-coupled monocarboxylate transporter-1 
SCFA  short chain fatty acids 
TGF  transforming growth factor 
TFF-3  trefoil factor-3 
Th  T-helper 
TLR  toll-like receptor 
TNBS  2,4,6-trinitrobenzene sulfonic acid 
TNF  tumor necrosis factor  
TNFR  tumor necrosis factor receptor 
Tollip  toll interacting protein 
UC  ulcerative colitis 
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CHAPTER I 
INTRODUCTION 
 
Patients with chronic ulcerative colitis (UC) have a 10-fold greater risk than 
healthy individuals to develop colorectal cancer (CRC), one of the most commonly 
diagnosed cancers (1, 2).  Regular screenings, early detection, and a diet rich in fruits 
and vegetables are a few ways to reduce risk of colon cancer (2, 3). These food groups 
are nutrient-dense and a good source of fiber, phytochemicals, and antioxidants (3).  
Peaches, for example, contain high levels of phenolic compounds like quercetin and 
chlorogenic acid (4).  In peaches, as well as nectarines and plums, it has been shown that 
phenolic content correlates with antioxidant activity (5).  Antioxidants, or free radical 
scavengers, can inhibit the development of colon cancer.  Quercetin and chlorogenic 
acid may also have anti-inflammatory properties, by reducing expression of some pro-
inflammatory cytokines (6, 7).  Due to their poor absorption, phenolic compounds reach 
the colon undigested, where they are metabolized by the microbiota (8, 9).  Exposure of 
the microbiota to phenolic compounds can alter the composition of bacterial populations, 
in addition to altering their function and fermentation rates and products.  Quercetin and 
chlorogenic acid alter the luminal environment and inflammatory pathways in the colon, 
suggesting that quercetin and chlorogenic acid may have potential for mitigation of 
inflammation and injury repair in chronic UC (5, 6, 8, 10-15).  
___________________ 
This thesis follows the style and form of The Journal of Nutrition. 
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Overview of Inflammatory Bowel Diseases 
 
Inflammatory bowel diseases 
The incidence and prevalence of inflammatory bowel diseases (IBD), such as 
ulcerative colitis (UC) and Crohn’s disease (CD), has increased in the United States, 
Canada, and Western Europe since the 1980’s (16, 17).  In fact, IBD is one of the top 
five digestive diseases in the United States, with UC being more prevalent (up to 
238/100,000) than CD (17, 18).  Unlike the gastrointestinal (GI) inflammation observed 
in CD, the inflammation characteristic of UC is localized to the distal colon and, because 
colon cancer is more prevalent in the distal colon and rectum, patients with UC are at a 
particularly high risk of developing colon cancer (1, 17).  Therefore, identifying dietary 
modifications that suppress inflammation, such as that occurring in UC, will not only 
reduce the morbidity associated with UC, but it may also serve to reduce the incidence 
of colon cancer.   
 
Ulcerative colitis 
In a healthy colon, the mucosa creates a protective barrier, separating the outside 
environment (luminal contents) and inside the body. A healthy mucosal barrier is 
characterized by functioning goblet cells, adequate mucin production, and strong tight 
junctions between epithelial cells (Fig. 1).  UC is characterized by a reduction of goblet 
cells (mucin production) and thinning of the protective mucus, resulting in increased 
exposure of intestinal cells to luminal contents and bacteria (Fig. 2) (1, 19-21).  
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FIGURE 1 Epithelial cells are the colon’s primary defense against the outside 
environment (luminal contents).  A healthy and well-maintained epithelium, in addition 
to adequate production of protective mucin is necessary for healthy colonic tissue. 
 
 
 
 
FIGURE 2 In active UC, impaired mucin production and decreased integrity of the 
epithelium leads to an increased exposure of the lamina propria to the luminal contents.  
This causes severe immune and inflammatory responses. 
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The increased exposure of colonocytes to luminal contents can cause epithelial injury, 
allowing infiltration of fecal material and bacteria into the lamina propria, triggering 
inflammation in the both the epithelium and lamina propria of the distal colon.  
 
Diet and Colon Health 
 
Phytochemicals in the diet 
Diets rich in fruits and vegetables are associated with a reduced risk of many 
diseases, including colon cancer and inflammatory bowel disease (IBD) (2, 3, 22). Fruits 
and vegetables are good sources of fiber, vitamins, and minerals, as well as many 
different types of phytochemicals.  Phytochemicals are secondary metabolites 
synthesized by plants, and include chemical classes such phenols, anthocyanins, and 
flavonols.  The composition of phytochemicals varies between not only the types of 
fruits and vegetables, but also between the genotypes of a single fruit. 
Stonefruits, such as peaches and plums, are of particular interest since they are 
high in phenolic compounds (4, 5, 11).  Peaches and plums contain high levels of 
quercetin and chlorogenic acid, two bioactive compounds that could be used as 
preventative or therapeutic agents in disease (4, 5, 8, 11, 15).  Stonefruit contain a 
variety of bioactive compounds, but chlorogenic acid and quercetin are found at very 
high concentrations compared to other bioactive compounds (4). 
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Quercetin and chlorogenic acid in the diet 
Like all phytochemicals, quercetin and chlorogenic acid are synthesized by 
plants, and therefore are only found in plant foods. Quercetin, the main flavonol in the 
diet, is found in varying concentrations in a variety of fruits and vegetables (Fig. 3a).  
Chlorogenic acid, an ester of caffeic and quinic acids, is the most abundant 
hydroxycinnamic acid in the diet, found in high concentrations in coffee and the skins of 
fruits, such as apples and peaches (Fig. 3b) (4, 9, 11).  In addition to the widespread 
presence of these parent compounds in the diet, there are several derivatives of each 
compound that can be found in each food item.  For example, neochlorogenic acid, an 
isomer of chlorogenic acid, is also found in high levels in peaches and plums (4, 5).  
Quercetin is most often consumed as a glycoside, where quercetin aglycone is bound to a 
carbohydrate molecule. Quercetin aglycone and caffeic acid are found as several esters 
and isomers in varying concentrations in plant foods. 
 
(a) (b)  
FIGURE 3 Quercetin is shown as quercetin aglycone (a), not bound to a carbohydrate 
molecule.  Chlorogenic acid (b) is an ester of caffeic acid and quinic acid. 
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Quercetin and chlorogenic acid in colon health and colonic inflammation 
It has been demonstrated that phenolic extracts containing quercetin and 
chlorogenic acid have anti-cancer and anti-inflammation effects in vitro and in vivo.  (A 
detailed description of the pathways involved in the regulation of inflammation is 
provided in the section following this overview.) In lipopolysaccharide (LPS)-stimulated 
murine macrophages, phenolic extracts of Kakadu plums suppressed inflammation by 
reducing levels of cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) 
(23).  Kakadu plum extracts also decreased phosphorylation and degradation of IKBα, 
the inhibitory subunit of nuclear transcription factor- κB (NF-κB) (23).  Although not a 
stonefruit, Ginkgo biloba extract inhibits tumor necrosis factor (TNF)-α, NF-κB, and 
interleukin (IL)-6 expression in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced 
murine colitis, possibly due to its high content of quercetin aglycone (24).  Phenolic 
extracts can contain a variety of bioactive compounds, but there is sufficient evidence 
that quercetin and chlorogenic acid play a major role in contributing to the anti-
inflammatory properties observed. 
Several studies have evaluated quercetin and chlorogenic acid in inflammation 
models.  Observing each compound individually, rather than as a part of their respective 
phenolic extracts, provides more information on how each compound contributes to anti-
inflammatory properties.  Quercetin has been studied extensively in vivo, inhibiting 
inflammation in acute dextran sodium sulfate (DSS)-induced colitis (6).  Suppressing 
activation of NF-κB and expression of COX-1 and COX-2, quercetin may play a strong 
anti-inflammatory role by decreasing expression of pro-inflammatory cytokines 
7 
downstream of NF-κB (6, 15).  Quercetin has also shown to enhance epithelial barrier 
function in vitro by increasing expression of claudin-4, a tight junction protein (25).  
This flavonol may be important for colon health and inhibiting inflammation by altering 
gene transcription of pro-inflammatory cytokines and tight junction proteins.  
Chlorogenic acid may also be beneficial due to its antioxidant properties, 
although there is limited in vivo data defining the effects of chlorogenic acid in colitis 
(9).  In vitro, chlorogenic acid inhibits DNA damage and the formation of mutagenic and 
carcinogenic compounds (9).  Other esters of caffeic acid have been shown to have 
protective effects in vitro, through inhibition of lipoxygenase and cyclooxygenase 
enzymes (26).  Metabolites of lipoxygenase (leukotrienes) and cyclooxygenase 
(prostaglandins) pathways play a role in inflammatory diseases and in tumorigenesis 
(26).  This in vitro data suggests that chlorogenic acid could not only protect against 
inflammation, but also reduce cancer risk by acting as an antioxidant and reducing 
production of prostaglandins.  Few in vivo studies have been reported on the anti-
inflammatory effects of chlorogenic acid.  However, hydrocaffeic acid, a derivative of 
caffeic acid, has shown to alleviate DSS-induced increases in IL-1β, TNF-α, and IL-8 
(7).  Upon reviewing previous in vitro and in vivo studies, chlorogenic acid may be 
protective through a variety of pathways, including those that regulate inflammation in 
the colon.  
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Inflammation in the Colon 
 
Nuclear transcription factor-κB pathway  
Inflammatory mediators, along with pro-inflammatory cytokines, can have varied 
effects based on the type of cell.  For example, cyclooxygenase-2 (COX-2) limits 
bacterial translocation into the lamina propria when expressed in epithelial cells, but can 
lead to neoplasia and tumorigenesis when expressed in the lamina propria (2, 27). Like 
COX-2, the downstream effects of nuclear transcription factor kappa-B (NF-кB) vary 
depending on the type of cell in which it is being expressed (Fig. 4) (27).  
In order to have downstream effects, NF-κB must be activated.  NF-κB is present 
in the cytoplasm of cells in its inactive form, bound to the inhibitory molecule IκΒα.  
NF-κB is activated by the presence of pro-inflammatory molecules, like interleukin (IL)-
1 and tumor necrosis factor-α (TNF-α) (20, 21, 27, 28).  IL-1 is one of the primary 
cytokines responsible for triggering the NF-кB-inflammation cascade (21, 29). NF-κB 
can also be activated through toll-like receptor (TLR) pathways, which are activated by 
interactions with bacterial cell components (21, 30).   
 
9 
 
FIGURE 4 Effects of NF-κB activation vary depending on the type of cell in which it is 
expressed. A review of the literature reveals that UC-associated injury triggers different 
responses in lamina propria and epithelial cells (1, 20, 21, 27). 
 
When IκΒα is phosphorylated and removed from NF-κB, activated NF-κB 
translocates to the nucleus where it induces transcription of cytokines (20, 21, 27, 30).  
There are multiple downstream effects of activated NF-κB including the stimulation of 
COX-2 expression, a key link between inflammation and cancer (2, 27).  NF-κB can 
increase expression of TNF-α, IL-1, and IL-6, and therefore propagate activation of NF-
κB in neighboring cells through positive feedback (20, 21, 28-31).   This positive 
feedback is further promoted by IL-6, which increases TNF-α and IL-1 expression (32).  
IL-1 and TNF-α also injure the colonic tissue by damaging the extracellular matrix and 
compromising the integrity of the protective mucosa (20).  The propagation of NF-κB 
activation by pro-inflammatory cytokines through positive feedback causes an 
uncontrolled inflammatory response. 
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NF-κB activation causes increased expression of other pro-inflammatory 
molecules including interferon (IFN)-γ, IL-6, IL-12, and COX-2 (20, 21, 28-33).  These 
cytokines are directly involved in mucosal damage and inflammation that is 
characteristic of active inflammatory bowel disease (IBD) (20, 32).  Just as immune 
signals can increase expression of pro-inflammatory cytokines, pro-inflammatory 
cytokines can alter the function, differentiation, and recruitment of immune cells.  For 
example, IFN-γ expression is stimulated by increased expression of IL-12, but IFN-γ 
also induces the differentiation of T-helper (Th)-1 cells (20, 32).  Th-1 immune 
response, while predominantly found in Crohn’s disease, is found in most experimental 
colitis models (32).  In chronic UC, both Th-1 and Th-2 immune responses are active 
(33).  IL-6 expression in colonocytes, for example, is elevated in UC and plays roles in 
both Th-1 and Th-2 immune responses (31).  In the lamina propria, dysregulation of NF-
κB signaling and Th-1 and -2 immune responses can lead to severe inflammation (pro-
inflammatory cytokines) and injury (degradation of the extracellular matrix). 
While NF-κB activation can exacerbate injury and inflammation in the lamina 
propria, NF-κB activation can be protective in epithelial cells.  For example, downstream 
effects of activated NF-κB in the epithelium include enhanced integrity of the epithelial 
cell barrier (anti-apoptosis) and limited bacterial translocation into the lamina propria 
(COX-2 expression) (2, 27, 32).  Through suppressing apoptosis and enhancing 
proliferation, NF-κB can facilitate restoration of epithelial barrier integrity and wound 
healing (1, 21).  Further evidence suggests NF-κB may play an anti-inflammatory role in 
colonic epithelial cells by suppressing further activation of NF-κB in neighboring cells 
11 
by stimulating expression of the inhibitory molecule IκBα (1, 20, 21, 28, 32).  While NF-
κB could exacerbate inflammation through increased activity in macrophages, activated 
NF-κB could play a protective role by promoting cell repair and integrity of the 
epithelial barrier (1, 20, 21). 
 
Tumor necrosis factor-α effects on cell cycle  
Expression of tumor necrosis factor (TNF)-α is increased in colitis, but can have 
numerous downstream effects (33).  Not only does TNF-α stimulate inflammation and 
activate immune cells, it also influences the cell cycle, altering proliferation and cell 
death in the epithelium (Fig. 5) (31). Tumor necrosis factor receptor (TNFR)-1 mediates 
cell death, cytokine production, and can affect targeted gene expression (31).  Through 
receptor interacting protein (RIP) and caspase-8, TNFR-1 is able to induce apoptosis and 
necrotic cell death (34).  Apoptosis, or programmed cell death, differs from necrotic cell 
death.  In necrotic cell death, the cell lyses, releasing contents of the cell, including pro-
inflammatory cytokines.  Activation of TNFR-1 could be the reason why both necrosis 
and apoptosis are observed in inflammation-associated cell death.  
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FIGURE 5 TNFR-1 and -2 stimulation causes biological responses involving 
inflammation and the cell cycle. TNFR-1 stimulates inflammation by activating NF-κB 
and cell death through apoptosis and necrosis.  TNFR-2 promotes cell survival through 
the anti-apoptotic signals of NF-κB, in addition to the increased expression of pro-
inflammatory cytokines associated with activated NF-κB. 
 
Tumor necrosis factor receptor (TNFR)-2 also plays a role in the cell cycle 
during inflammation, although it is responsible for cell proliferation and survival, rather 
than cell death (31).   Some downstream effects of TNFR-2 overlap with effects TNFR-
1, while some downstream effects are independent of TNFR-1 (31).  Like TNFR-1, 
TNFR-2 activates NF-κB, resulting in anti-apoptotic signals, promoting cell survival 
(31).  In UC, TNFR-2 expression is elevated, possibly due to the increased 
concentrations of pro-inflammatory cytokines like TNF-α and interleukin-6 (IL-6) (31).  
13 
While an elevation in TNFR-2 has the potential to be beneficial for cell survival, the 
elevations of NF-κB activity via TNFR-2 can increase inflammation.  This provides 
further support that proper expression of TNFR-1 and -2 and tight regulation of NF-κB 
activation is vital for healthy colonic tissue.  Despite the protective mechanisms of 
TNFR-2, its increased expression could increase the inflammatory response observed in 
UC.  
 
Microbiota Homeostasis and Metabolism 
 
Intestinal microbial interactions through Toll-like receptors 
Toll-like receptors (TLRs) are a family of receptors found in a variety of cells, 
including epithelial cells in the gastrointestinal (GI) tract.  Normally, TLR expression is 
low in epithelial cells, so the large concentrations of commensal bacteria do not cause an 
immune response (32).  TLR stimulation by pathogenic or misrecognized commensal 
bacteria in the GI tract causes increased recruitment and activation of neutrophils, 
enhancing the innate immune response (35). In addition to an acute inflammatory 
response, TLR are thought to play a role in chronic inflammatory processes, like that 
found in ulcerative colitis (UC).   
TLRs trigger downstream inflammatory responses via the TLR signal 
transduction molecule myeloid differentiation protein-88 (MyD88) (Fig. 6) (35, 36).  
MyD88 activates kinases that activate NF-κB kinase (IΚΚ), and therefore NF-κB (35). 
Although MyD88-independent signal transduction does exist in TLR pathways, similar 
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transduction molecules will also activate NF-κB (35). In chronic inflammatory diseases 
like UC, the impaired regulation of TLR can be detrimental to intestinal inflammation. 
 
 
FIGURE 6 TLR mediates activation of NF-κB via MyD88 and other transduction 
molecules.  My-D88-stimulated activation of NF-κB is inhibited by TOLLIP. 
 
Tight regulation of TLR limits cell damage and prevents unnecessary immune 
and inflammatory responses.  Specific endogenous and exogenous TLR ligands can 
activate TLR and downstream inflammatory processes (35).  Exogenous TLR ligands 
vary by the type of TLR, but all TLR are activated in bacterial or viral infection (35). 
TLR-2 is stimulated by gram positive bacterial cell wall components and can play a 
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protective role through the maintenance of the epithelial barrier (35, 37).  Maintaining 
epithelial barrier integrity, TLR-2 increases tight junction protein expression and 
enhances the function of mucin-producing goblet cells (37, 38). When TLR-2 is 
activated, trefoil factor-3 (TFF-3) expression is increased, a peptide important for 
epithelial barrier integrity (38, 39).  TFF-3 is thought to enhance injury repair through 
enhanced cell survival and reduced recruitment of inflammatory cells (38, 39).  In 
TNBS-induced colitis, a reduced expression of TFF-3 has been observed, which is 
reflected by the high levels of injury and inflammation seen in colitis (39).  TLR-2 also 
has downstream anti-inflammatory effects, suggesting possible protection in UC (38).  In 
addition to TLR-2, TLR-9 also functions to protect the epithelium.  TLR-9 is stimulated 
by unmethylated CpG motifs, motifs most often found in prokaryotic and viral DNA (32, 
37, 40, 41).  CpG motifs are cytosine and guanidine nucleotides found next to each 
other, which are tightly regulated (suppressed and/or methylated) in mammalian DNA 
(40).  TLR-9, a pattern-recognition receptor, is unique in that it can differentiate between 
self and non-self CpG DNA motifs (40).  If TLR-9 is dysfunctional, self CpG DNA can 
be identified as non-self, causing an auto-immune response (37).  In colitis, TLR-9 
stimulation can be protective via increased expression of IFN-α/β (32, 40).  These type I 
IFNs can suppress dextran sodium sulfate (DSS)-induced colitis and prevent epithelial 
barrier dysfunction (41).  Although TLR-2 and TLR-9 play an active role in maintaining 
epithelial barrier integrity, some TLR modulate microflora-mediated protection against 
pathogenic bacteria. 
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Some TLR, like TLR-4 and -5, identify pathogenic bacteria and trigger responses 
to protect the body from the pathogens. TLR-4 plays an important role in commensal 
microflora-mediated protection (37).  TLR-4 will identify pathogenic bacteria causing an 
inflammatory response (NF-κB activation), neutralizing the pathogenic threat to the 
epithelial cells (35, 37).  Normally, NF-κB is activated via the TLR-MyD88 pathway.  
However, TLR-4 is able to activate NF-κB using different signal transduction molecules 
(TRIF, RIP-1) (37).  In addition, the presence of inflammatory cytokines, like TNF-α 
and IFN-γ, have shown to increase expression of TLR-4 in vitro, which may exacerbate 
TLR-4-induced inflammatory response (37).  In UC, pathogenic bacteria populations 
may be higher than normal (32, 42).  With an increased population of pathogenic 
bacteria and an increased number of TLR-4 receptors on epithelial cells, this can lead to 
severe inflammation.  Another inflammation-associated TLR is TLR-5, which is 
stimulated by flagellin, a bacterial component found in both commensal and pathogenic 
bacteria (35, 37).  If pathogenic bacteria are present, or commensal bacteria are 
misrecognized to be pathogenic, TLR-5 stimulates cytokine and chemokine secretion in 
intestinal epithelial cells, via NF-κB (32, 37).  In UC, an intolerance of commensal 
bacteria develops, leading to inflammatory and exaggerated immune responses. 
Since colonic epithelial cells are constantly in contact with bacteria, it is 
important that non-pathogenic, commensal bacteria do not trigger an immune response.  
This is achieved by an increased expression of toll like receptor inhibiting protein 
(Tollip) in response to non-pathogenic bacteria and transforming growth factor (TGF)-β-
regulation of immune response (43, 44). Tollip allows colonic tissue to tolerate the 
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presence of the microflora, inhibiting TLR-induced pro-inflammatory responses (43).  
Tollip expression is seen to be similar in patients with and without UC, while a 
decreased sensitivity of TGF-β is observed in colitis (43, 44).  Decreased sensitivity of 
TGF-β causes an increase in T cell-mediated autoimmune and auto-inflammatory 
responses (44). Although Tollip activity is normal in UC, the decreased sensitivity of 
TGF-β and the over-stimulation of TLR by bacteria are responsible for the increased 
TLR-induced inflammatory and immune responses.  
In the GI tract, TLR play an important role in controlling homeostasis, injury 
repair, and prevention of injury.  Whether through maintaining the epithelial barrier or 
preventing pathogenic or viral infection, TLR are important for GI health.   The 
increased expression of TLR, dysregulation of TLR signaling, and misrecognition of 
commensal bacteria as pathogens, however, can be detrimental to health status.   
 
Role of short chain fatty acids in colon health 
Fermentation of substrates, including dietary fiber and other carbohydrate 
structures, by colonic microflora plays a part in colonic health and homeostasis of 
colonocytes.  Dietary fiber is not digested in the small intestine, so it reaches the colon 
where it is fermented by bacteria, yielding short chain fatty acids (SCFA) (45).   It is also 
a prebiotic, promoting a healthy, non-pathogenic microbial population (42, 46).  Dietary 
fiber not only affects the populations of bacteria found in the colon, but also their 
fermentation rates and patterns. 
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Release of SCFA causes beneficial changes to the luminal environment: 
decreased colonic pH, enhanced water and mineral absorption, and impaired growth of 
pathogenic bacteria (42). While the rate of fermentation is higher in the proximal colon, 
fermentation is still active in the distal colon, and therefore its benefits are applicable to 
the distal colon (42, 47).  Fermentation products vary, but the most important SCFA are 
butyric, acetic and propionic acids (45, 47, 48).  Butyric acid is particularly important, as 
it serves as a primary energy source for colonocytes and decreases production of pro-
inflammatory cytokines (via inhibition of NF-κB activation) (42, 49, 50).  In addition, 
butyrate decreases the activity of co-carcinogenic enzymes (42, 46).  In normal cells, 
SCFA stimulate epithelial cell proliferation and increase mucosal blood flow, improving 
epithelial barrier integrity (45, 46, 49).  SCFA are important for the homeostasis of both 
the microflora (inhibit growth of pathogenic bacteria), and the colonocytes (energy 
source and anti-inflammatory). 
An imbalance between healthy and pathogenic bacteria in the colon, or dysbiosis, 
is thought to trigger the onset of ulcerative colitis (UC) (32, 42).  Changes in the 
microbial population in the colon will not only alter SCFA concentrations in the lumen, 
but can also exacerbate immune and inflammatory responses.  Caffeic acid, a component 
of chlorogenic acid, has shown to inhibit growth of pathogenic bacteria, like Clostridium 
perfringens (51).  In addition, 3-(Quercetin-8-yl)-2,3-epoxyflavanone, a product of 
quercetin oxidation, has shown to have antibacterial activity against multidrug-resistant 
S. aureus and H. pylori (52). By influencing the populations of microbes present in the 
colon, chlorogenic acid and quercetin may contribute to changes in the amount and 
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relative distributions of SCFA produced.  Monitoring fecal SCFA levels and relative 
concentrations will therefore serve as a biomarker of changes in either microbial 
populations or their fermentation patterns.  
 
Metabolism of phytochemicals by the microbiota 
In addition to fermentation of fiber, the bacteria in the colon also metabolize 
phytochemicals like flavonols and phenols.  Chlorogenic acid is degraded by bacteria-
produced esterases into caffeic and quinic acids (53).  Quercetin, found as a glucoside, is 
extensively metabolized by the microbiota (53).  When metabolized, quercetin-3-O-
glucoside yields quercetin aglycone, formate, lactate, ethanol, and 3,4-
dihydroxyphenlyacetic acid, acetate, and butyrate (53).  Quercetin aglycone is thought to 
be more beneficial than its glucoside counterpart, as the aglycone is more effective at 
preventing experimental murine colon carcinogenesis than the glucoside (54).  
Therefore, breakdown of quercetin-3-O-glucoside is essential for release of the bioactive 
quercetin aglycone.  Since the microbiota is a vital component of quercetin and 
chlorogenic acid metabolism and absorption, it is safe to assume that changing levels of 
phytochemicals in the diet could impact the health, homeostasis, and proper function of 
the microbiota. 
 
Short chain fatty acid absorption  
While the microflora is needed for short chain fatty acid (SCFA) synthesis from 
fiber, transport proteins are necessary for proper absorption of SCFA into the epithelial 
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cells.  Absorption of SCFA can enhance water and ion transport across the epithelial cell 
membrane.  Proper water and electrolyte balance is important for gastrointestinal health, 
as water imbalance can lead to constipation or diarrhea.  A transport protein necessary 
for ion balance and SCFA absorption is sodium-coupled monocarboxylate transporter-1 
(SLC5A8).  SLC5A8 transports both SCFA and sodium into colonocytes (39).  The 
SCFA uptake is important for maintenance of luminal pH and transport of energy-
yielding substrate into the cells; sodium uptake is important for water balance.  Water 
and electrolyte imbalances exacerbate the symptoms of UC, so sufficient expression and 
localization of SLC5A8 in epithelial membranes is desired in the colon.  
Butyrate is an important energy source for colonocytes and is vital for the 
integrity of the epithelial barrier (39, 55).  Monocarboxylate transporter-1 (MCT-1) is an 
important transporter of butyrate into colonic epithelial cells, playing a key role in the 
maintenance of the epithelial barrier (39, 55).  In UC, a strong epithelial barrier can limit 
bacterial infiltration into the colonic tissue.  However, in dextran sodium sulfate (DSS)-
induced murine colitis, MCT-1 expression (both protein and mRNA levels), butyrate 
uptake, and butyrate utilization are reduced (55).  In fact, an indirect relationship 
between MCT-1 expression and colonic mucosal inflammation (IFN-γ and TNF-α) is 
observed in DSS-induced colitis (39, 55).  In UC, impaired production, uptake, and β–
oxidation of butyrate are observed (42, 45, 46, 50, 55, 56). The decreased absorption of 
butyrate observed in UC could impair butyrate’s ability to act as an energy source and an 
anti-inflammatory agent. 
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Summary 
 
 A review of the literature suggests that quercetin and chlorogenic acid may be 
beneficial in colitis.  Examination of both in vivo and in vitro studies provides sufficient 
evidence that both compounds have anti-inflammatory properties in colon cells.  
Expression of pro-inflammatory molecules is decreased by quercetin and chlorogenic 
acid through a variety of pathways.  NF-κB activation is primarily responsible for the 
increased expression of pro-inflammatory molecules, increasing inflammation in some 
cells, while activating protective mechanisms in others.  Quercetin down regulates NF-
κB, and therefore its downstream pro-inflammatory effectors.  Chlorogenic acid has also 
shown to reduce expression of pro-inflammatory molecules.  NF-κB activation and 
increased expression of pro-inflammatory cytokines can be triggered through multiple 
pathways including toll-like receptor and tumor necrosis factor receptor signaling.  Since 
there is little evidence suggesting which pathways are influenced by quercetin and 
chlorogenic acid, each pathway will be investigated.   
In addition, quercetin and chlorogenic acid may play a role in altering microbial 
populations, their fermentation rates, and ratios of short chain fatty acids (SCFA) in the 
colon.  Since these compounds are metabolized by the microbiota, they may function to 
promote survival of beneficial bacteria and/or inhibit growth of pathogenic bacteria.  In 
addition, quercetin and chlorogenic acid may alter fermentation of carbohydrates, 
altering the rates and/or ratios of SCFA released into the lumen.  These SCFA alter the 
luminal environment and can enhance water and mineral absorption.  One SCFA, 
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butyrate is the primary energy source for colonocytes, making its production and 
absorption a necessity for properly functioning colonocytes.  Butyrate has also shown to 
have anti-inflammatory properties, which could be beneficial in colitis.  As a result of 
this review, quercetin and chlorogenic acid will be examined individually to determine 
their effects on various aspects of inflammation in an in vivo murine model of chronic 
colitis. 
 
Objective of Study 
 
Based on current literature, we hypothesize that the stonefruit bioactive compounds, 
quercetin and chlorogenic acid, may protect against inflammation in a colitis/injury state 
via suppression of pro-inflammatory molecules, and regulation of the cell cycle and the 
luminal environment.  To assess the effects of quercetin and chlorogenic acid on 
inflammation and injury in the colon, this study aims to: 
- evaluate structural changes in colon crypts (injury and inflammation) 
- evaluate proliferation in colon crypts 
- quantify and characterize short chain fatty acid concentrations in fecal material 
- evaluate NF-κB activity in mucosal scrapings  
- quantify expression of genes involved in regulation of inflammation, injury repair, 
and SCFA transport
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CHAPTER II 
CHLOROGENIC ACID AND QUERCETIN MITIGATED DSS-INDUCED 
INCREASES IN IL-1 EXPRESSION AND DECREASES IN SLC5A8 
EXPRESSION 
 
Introduction 
 
Inflammatory bowel disease (IBD) is one of the top five digestive diseases in the 
United States, with ulcerative colitis (UC) being more prevalent than Crohn’s disease 
(17, 18).  Inflammation in UC is localized to the distal colon, and, because colon cancer 
is more prevalent in the distal colon and rectum, patients with UC are at a particularly 
high risk of developing colon cancer (1, 17).  The ultimate causes of ulcerative colitis are 
not known, however, the disease is associated with exaggerated immune responses to 
normal commensal microbiota, a probable dysbiosis in which the distribution of 
microflora is altered, and altered epithelial barrier function (32). Treatment regimens 
relying upon pharmaceuticals and biological therapies are currently inefficient in that 
they are often ineffective in approximately half of subjects (57).  Therefore, identifying 
alternative interventions, such as dietary modifications that suppress inflammation in the 
colon, by mediating the contributors to colitis or their downstream effects, will not only 
reduce the morbidity associated with UC, but it may also serve to reduce the incidence 
of colon cancer.   
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Diets rich in fruits and vegetables are associated with a reduced risk of many 
diseases, including colon cancer and IBD (2, 3, 22). Fruits and vegetables are good 
sources of fiber, vitamins, and minerals, as well as many different types of 
phytochemicals.  Stonefruits, such as peaches and plums, contain many phytochemicals 
with biological activity, including quercetin and chlorogenic acid (4, 5, 11).  Quercetin is 
the main flavonol in the diet, and chlorogenic acid, an ester of caffeic acid, is the most 
abundant hydroxycinnamic acid in the diet (4, 9, 11).  There are a limited number of 
studies that have attempted to determine the effect of stonefruits on colon health, with 
most of the work being conducted in vitro.  However, Yang and Gallaher (2005) found 
that consumption of dried plums alters activities of bacterial enzymes leading to a 
reduction in fecal levels of secondary bile acids, which are known irritants that can 
promote colon carcinogenesis (58).  Phenolic extracts of Kakadu plums have been 
reported to decrease activation of NF-κB and levels of cyclooxygenase (COX)-2 in LPS-
stimulated murine macrophages (23).  Since stonefruit extracts contain many different 
compounds, it is desirable to identify the protective mechanisms of each compound.  
In an attempt to begin to understand how the individual compounds in these 
extracts influence the colon, our lab demonstrated that quercetin reduces colon 
carcinogenesis in vivo, and that the suppression may have occurred in part due to a 
reduction in expression of pro-inflammatory mediators like COX-2 (15).  It has also 
been shown that quercetin suppresses activation of NF-κB in an acute model of colitis 
and enhances epithelial barrier function in vitro by increasing expression of claudin-4, a 
tight junction protein (6, 25).  In UC, epithelial barrier integrity is reduced, resulting in 
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increased paracellular transport of luminal contents, triggering immune and 
inflammatory responses (32).  The effects of quercetin on pro-inflammatory cytokines 
and epithelial integrity have not been studied in chronic colitis, however, and must be 
further investigated. 
Chlorogenic acid also may protect against inflammation, as well as 
inflammation-associated carcinogenesis.  Chlorogenic acid has demonstrated the ability 
to protect against carcinogenesis in vitro via inhibition of DNA damage and of formation 
of mutagenic and carcinogenic compounds (9).  Through inhibition of pro-tumorigenic 
enzymes, lipoxygenase and cyclooxygenase, esters of caffeic acid have shown to have 
protective effects in vitro (26).  Few in vivo studies have been reported on the anti-
inflammatory effects of chlorogenic acid.  However, hydrocaffeic acid, a derivative of 
caffeic acid, alleviates DSS-induced increases in IL-1, TNF-α, and IL-8 in acute colitis 
(7).  The anti-cancer and anti-inflammatory properties demonstrated in vitro and in vivo 
warrant further investigation of chlorogenic acid in chronic colitis. 
Diet can not only alter the production of pro-inflammatory cytokines, but can 
also influence the microbial populations in the colon (59).  Chlorogenic acid and 
quercetin are both metabolized by bacterial-produced enzymes and, therefore, may 
influence fermentation patterns (53).  In vitro, quercetin and chlorogenic acid have 
shown to have anti-microbial properties (51, 52).  Through changes in the microbial 
populations and their fermentation patterns, these bioactive compounds could impact the 
epithelium and production of pro-inflammatory cytokines. 
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The purpose of this study was to evaluate the effects of quercetin and chlorogenic 
acid on inflammation, injury, and SCFA metabolism in the colon using a chronic model 
of colitis.  To determine the mechanisms involved, the influence on NF-κB, toll-like 
receptor (TLR), and tumor necrosis factor receptor (TNFR) pathways were examined.  
Based on the literature, we hypothesized that stonefruit bioactive compounds, quercetin 
and chlorogenic acid, may protect against inflammation in a chronic colitis/injury state 
via suppression of pro-inflammatory molecules, and alteration of the cell cycle and of 
the luminal environment. 
 
Materials and Methods 
 
Animals and study design 
Animals in this project were treated in accordance with National Institutes of 
Health guidelines using a protocol approved by the Texas A&M University Animal Care 
Committee.  Sixty-three male weanling Sprague-Dawley rats (Harlan Sprague-Dawley, 
Houston, TX) were acclimated for 6-9 d and then assigned to one of three diet groups 
(basal, 0.45% quercetin, 0.05% chlorogenic acid), which were further divided into 
dextran sodium sulfate (DSS, 3%) and control (0% DSS) groups (Fig. 7). Previously, our 
lab has used 0.45% quercetin in the diet, which inhibited expression of COX-1 and 
COX-2 in an AOM model (15).  Therefore, this level of quercetin was used as a positive 
control.  Assuming the rats consumed approximately 20 g/d of diet, this would result in 
an intake of 0.09 g quercetin/d and 0.01 g chlorogenic acid/d.  Adjusting for body 
 27 
weight, this is equivalent to a human consuming 1.8 g quercetin/d and 0.2 g chlorogenic 
acid/d.  In order to get 1.8 g quercetin/d, humans would need to supplement a diet rich in 
fruits and vegetables with quercetin supplements.  On the other hand, drinking ~60 mL 
of coffee (strong brew, pale roast robusta) is sufficient to obtain this level of chlorogenic 
acid (60).  This amount of chlorogenic acid can also be obtained in the diet by 150-300 g 
of peaches, plums, or nectarines (4).   
 
 
FIGURE 7 Twenty-one rats were assigned to each diet (basal, 0.05% chlorogenic acid, 
0.45% quercetin), with 10 rats assigned to the control (distilled H2O), and 11 rats 
assigned to the 3% DSS treatment group in each diet.  
 
 
 
After 3 wk of consuming the experimental diets, DSS animals began DSS 
treatment (Fig. 8).  DSS animals were given a total of three 48-h DSS treatments (3% 
DSS in H2O), separated by 2 wk, during which they received distilled H2O.  Control 
animals received only distilled H2O.  Since DSS is one of the most widely used reagents 
for inducing colitis, the clinical and histopathological characteristics, as well as 
associated gene expression, are already known to reflect aspects of human UC (1, 61, 
62).  Clinical symptoms exhibited by animals on DSS treatment include weight loss, 
diarrhea, and blood in the stool (61). Although DSS is often used as an acute injury-
inducing agent, the histopathology, inflammatory cytokines, microflora effects, and 
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clinical symptoms of DSS reflect UC.  To mimic human chronic UC, animals were 
given multiple low-dose DSS-treatments with periods of remission (1).  
 
 
FIGURE 8 Animals were acclimated before starting experimental diets.  After 3 wk of 
experimental diets, DSS exposures began (3% DSS for 48 h, 2 wk separation, 3 
treatments total).   
 
 
 
Body weight and dietary intake 
Body weights were recorded throughout the experiment: wk 0, 3, 4, 6, 8, 9.  
Body weights were used to assess growth rates and weight loss that may be attributed to 
onset or progression of disease.  Intake was measured at wk 3, 6, and 9.  Body weights 
and intake were measured twice over 48 h and averaged.  Measuring dietary intake 
ensured that the animals received adequate nutrition and a known amount of bioactive 
compounds, in addition to monitoring disease state, since intake is usually decreased in 
UC.  Experimental diets were extracted with methanol and analyzed using mass 
spectroscopy to verify levels of quercetin (0.466%) and chlorogenic acid (0.047%).  
 
Fecal output and moisture content 
Feces was collected at seven time points corresponding to before and after each 
DSS treatment, and prior to termination.  After being observed for consistency and 
DSS 
Treatment 
3 wk 
Start Diet 
DSS 
Treatment 
2 wk 2 wk 2 wk 
DSS 
Treatment Termination 
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presence of blood, fecal samples were placed in vials.  Fresh samples were collected 
within 15 min of defecation over a 48 h period and snap-frozen in liquid nitrogen, and 
stored at -80ºC until further analysis.  Daily fecal production was determined using 
samples collected over 24 h, which were weighed, snap-frozen, and stored at -80ºC until 
further analysis.  Fecal production was calculated by averaging the daily fecal weights if 
two consecutive 24-h collections occurred.  Fecal moisture content was determined to 
track disease state in fresh fecal samples. Feces were dried at 60-80°C for 24-48 h, then 
placed in a dessicator until cooled (2-4 h).  This process was repeated until a constant 
weight was obtained for each sample (49). In fresh fecal samples, fecal moisture content 
was used to calculate SCFA concentrations on a dry weight basis, which was combined 
with the 24 hour fecal production data to estimate daily short chain fatty acid 
concentrations (See Appendix A for calculations).  
 
Short-chain fatty acid analysis 
 SCFA concentrations were quantified in fecal samples collected before and after 
the first and third DSS treatments and prior to termination.  Samples (~0.30 g) were 
powdered, prepared, and analyzed as previously described using liquid-gas 
chromatography, with few modifications (49).  To each diluted supernatant (100 µL 
supernatant, 100 µL 70% ethanol), 200 µL internal standard solution (heptanoic acid in 
70% ethanol) and 20 µL H3PO4 was added.  A Varian CP3841 Autoinjector injected 1 
µL into a Varian 3900 GC fitted with an HP-FFAP 30 m, 0.53 mm i.d. capillary column 
(19095F-123, Agilent, Santa Clara, CA). A 1 m deactivated glass capillary precolumn 
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(25703, Supelco, Bellmonte, PA) was in place as a guard column.  Data were integrated 
and plotted using the Varian Star Workstation Program (Varian, Walnut Creek, CA).  
Standards and a blank were run before and after the sample runs each day to calculate 
SCFA (acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, valeric 
acid) concentrations in the feces. Fecal production and moisture content data were used 
to calculate SCFA concentrations on a dry weight basis and 24-h SCFA excretion (See 
Appendix A for calculations).  
 
Injury and inflammation scores 
From the distal colon, 1 cm was removed and fixed in 4% paraformaldehyde 
(PFA) (400 mL 1x PBS, 100 mL 20% PFA) (Fig. 9).  PFA sections were stained with 
hematoxylin and eosin (H&E), a stain commonly used for histopathological analyses 
(63).  Histopathological signs induced by DSS include crypt distortion and loss, 
infiltration of immune and inflammatory cells, as well as edema and ulceration (1, 61, 
62).  Stained sections were scored by a board-certified pathologist for injury (0-3) and 
inflammation (0-3) (See Appendix A for scoring details) (63).   
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FIGURE 9 Once the colon was rinsed with PBS, two 1 cm sections were removed from 
the distal end of the colon.  The sections were fixed in either 70% EtOH or 4% PFA, as 
described.  From the remaining tissue, aliquots of mucosal scrapings were homogenized, 
and stored in denaturation solution or protein buffer. 
 
 
 
Proliferative index, zone, and crypt height 
 From the distal colon, an additional 1 cm was removed and fixed in 70% ethanol 
(EtOH).  The staining procedure (concentration of antibodies and incubation times) was 
optimized using manufacturer suggestions (Vector Labs and Covance) to the protocol 
described by Vanamala et al. (14).  Tissues were pre-treated with Reveal Decloaker 
(Biocare Medical, Concord, CA), then stained with Vectastain® Elite® ABC Kit 
(Vector Lab, Burlingame, CA), and purified proliferating cell nuclear antigen (PCNA) 
monoclonal antibody (SIG-3523, Covance, Emeryville, CA). To visualize positively 
stained cells, slides were then stained with 3,3’-diaminobenzadine (DAB) Substrate Kit 
for Peroxidase (SK-4100, Vector Lab, Burlingame, CA) until optimal staining intensity 
was reached (30-60 s) and counterstained with hematoxylin solution (HHS16, Sigma 
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Aldrich, St. Louis, MO). Twenty-five crypt columns per animal were observed to 
calculate crypt column height, proliferative index, and proliferative zone as previously 
described (14).   
 
NF-κB activity   
Post mortem, the colon was removed and rinsed twice with RNAse free PBS.  
Mucosal scrapings were collected using a RNase free slide and RNase free glass surface 
on ice.  An aliquot of mucosal scrapings was homogenized in protein buffer ([1 mL 500 
mM Tris-HCl (pH 7.2, Sigma), 2.5 mL of 1.0 M sucrose (Sigma), 100 µL 200 mM 
EDTA (pH 7.6, Sigma), 100 µL 100 mM EGTA (pH 7.5, Aldrich), 1.25 µL 0.4 M NaF 
(Sigma), 4.554 mL H2O, 1 mL 10% Triton X-100 (Sigma), 100 µL 10 mM 
orthovanadate (Sigma), 400 µL Protease Inhibitor (Sigma)] as previously described by 
Leonardi et al. (64).  Supernatant was aliquoted and stored at -80ºC until analysis.   One 
protein aliquot was used for the NF-κB activity analysis, using an ELISA based method 
(6).  The TransAM® NF-κB Chemi p65 kit (40097, Active Motif, Carlsbad, CA) was 
used as described in the manufacturer’s instructions.  NF-κB activity is reported in 
relative luminescence units, which is the level of NF-κB activation in the samples 
compared to the positive control (1 µL Jurkat nuclear extract, 19 µL Complete lysis 
buffer/well) provided in the TransAM® NF-κB Chemi p65 kit.  Activity was normalized 
to protein concentrations, which were quantified using the Coomassie Plus (Bradford) 
Assay Kit (23236, Thermo Scientific, Rockford, IL). 
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Real time RT-PCR 
A second aliquot of the mucosal scrapings was homogenized in denaturation 
solution (ToTALLY RNA™ Kit, Ambion, Austin, TX) and the mRNA samples were 
stored at -80ºC until further analysis (15).  As described by Warren et al., total mRNA 
was isolated and treated with DNase, with the additional use of Phase Lock Gel™ Tubes 
(5 Prime, Gaithersburg, MD) for centrifugation (15).  The Phase Lock Gel™ Tubes aid 
in the separation of phases, limiting the concentrations of contaminants in the mRNA 
samples.  Before PCR analysis, mRNA quality was measured using an Agilent 
Bioanalyzer, while mRNA concentrations were measured using spectrophotometry.  
Using Superscript™ III Reverse Transcriptase Kit (Invitrogen, Carlsbad, CA), Taqman® 
Array Microfluidic Cards (Applied Biosystems, Foster City, CA), ABI 7900 HT 
thermocycler (Applied Biosystems, Foster City, CA), and SDS 2.4 software (Applied 
Biosystems, Carlsbad, CA) real time RT-PCR was performed on select gene targets 
(TFF-3, TGF-Β, TLR-2, TLR-4, TLR-5, TLR-9, TNF-α, TNFR-1, TNFR-2, Tollip, 
FGF-2, IκΒα, IL-1, IL-6, IL-12, MyD88, COX-2, RelA/p65, RIP kinase, SLC5A8, and 
MCT-1).  The use of Taqman® Array Microfluidic Cards reduces the potential for 
loading differences for each of the targets.  These targets allowed for analysis of several 
pathways that contribute to regulation of processes involved in maintaining colon health.  
To complement NF-κB activity data, RelA/p65 and IκΒα were measured, in addition to 
the pro-inflammatory cytokines downstream of NF-κB  (IL-1, IL-6, IL-12, TNF-α, 
COX-2, TGF-B).  Upstream of NF-κB are the TLR (TLR-2, TLR-4, TLR-5, TLR-9, 
MyD88, Tollip) and TNFR (TNFR-1, TNFR-2, RIP kinase, TNF- α) pathways, both of 
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which can function to activate NF-κB.  In addition, injury repair molecules TFF-3 and 
FGF-2 were measured since DSS is an injury model, in addition to an inflammation 
model.  Lastly, SCFA transport proteins MCT-1 and SLC5A8 were measured to 
complement SCFA concentrations measured in the feces.  Data was analyzed using the 
comparative CT (ΔΔ CT) method in RQ Manager 1.2.2 (Applied Biosystems, Carlsbad, 
CA), with 18S as the calibrator gene. 
 
Statistics  
Data were analyzed using a two-way analysis of variance (ANOVA) (diet, 
treatment, diet*treatment) using SAS 9.3 software.  All data are reported as least squares 
(LS) means ± standard error of the mean (SEM), using a significance of p<0.05. 
 
Results 
 
Body weight, intake, and fecal moisture content 
There were no differences in body weight at baseline, or wk 3, 4, 6, 8, and 9 with 
diet or treatment (See Appendix B).  There were no significant differences in intake at 
wk 3 (prior to first DSS treatment) or 9 (prior to termination) with experimental diets 
and DSS treatment (Table 1).  At wk 6 (~d 63), non-DSS treated animals on the 
quercetin diet had significantly lower intake than non-DSS treated animals consuming 
the basal diet (p=0.01) and DSS-treated animals consuming the quercetin diet (p=0.02). 
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TABLE 1 Intake (g) measured prior to DSS treatment, immediately following the 
second DSS treatment, and prior to termination1 
 
wk 
Basal Diet Chlorogenic Acid Diet Quercetin Diet 
Control       DSS Control DSS Control DSS 
3 16.6 ± 0.6a 17.5 ± 0.5a 16.2 ± 0.5a 16.2 ± 0.5a 16.3 ± 0.5a 16.5 ± 0.5a 
6 20.4 ± 0.8c 19.4 ± 0.7abc 19.5 ± 0.9abc 18.1 ± 0.8ab 17.6 ± 0.8a 20.0 ± 0.7bc 
9 20.0 ± 0.9a 19.4 ± 0.8a 19.4 ± 0.9a 20.7 ± 0.8a 19.3 ± 0.9a 20.1 ± 0.8a 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=7-11 rats/group. 
 
 
 
Severity of disease was not reflected in body weight or intake, but fecal moisture 
content increased with DSS treatment (p<0.05) and remained elevated compared to non-
DSS treated animals (p<0.05).  Even after 2 wk of recovery, animals were unable to 
recover to control levels of fecal moisture content (Fig. 10).  Prior to termination, DSS 
animals persisted to show symptoms of disease, including increased fecal moisture 
content (p<0.05).  In addition to causing diarrhea, there was an increased incidence of 
blood in the stool and diarrhea with DSS treatment (data not shown). 
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FIGURE 10 Baseline measurements revealed no diet differences in fecal moisture 
content (n=8-11 rats/diet). DSS increased fecal moisture content (p<0.05) and remained 
significantly higher than control animals for the remainder of the experiment. See 
Appendix B for actual values. 
 
 
 
SCFA concentrations 
Due to the severity of diarrhea observed in DSS-treated animals, SCFA 
concentrations were corrected for percent water in the feces and reported on a dry weight 
basis (For calculations, See Appendix B). After the induction of DSS treatment (post 
DSS 1), acetic acid (p<0.05), butyric acid (p<0.05), and total SCFA (p<0.05) 
concentrations increased for all diets compared to their non-DSS counterparts (See 
Appendix A).  This pattern was also observed after the final DSS treatment for acetic 
acid (p<0.0001), butyric acid (p<0.05), and total SCFA (p<0.0001) (Fig. 11).  The final 
measurement of SCFA concentrations is most reflective of the possible luminal 
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environment close to termination (Fig. 12).  After the final 2 wk recovery, all DSS 
treated animals showed significantly higher levels of SCFA (acetic acid, p<0.05; butyric 
acid, p<0.05; total SCFA, p<0.05) compared to their non-DSS counterparts.   
 
 
FIGURE 11 SCFA concentrations following the final DSS treatment revealed 
significant increases in acetic acid (p<0.0001), butyric acid (p<0.05), and total SCFA 
(p<0.0001; n=8-11 rats/diet). Relative concentrations of acetic acid were increased 
(p<0.05), while relative concentrations of butyric acid were decreased (p<0.05) by DSS 
treatment in all diet groups. See Appendix B for actual values. 
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FIGURE 12 Prior to termination, SCFA concentrations remained significantly higher in 
DSS-treated animals compared to control animals (acetic acid, p<0.05; butyric acid, 
p<0.05; total SCFA, p<0.05; n=8-11 rats/diet).  Animals fed a basal diet had comparable 
relative concentrations of acetic acid between DSS and non-DSS treated rats.  Relative 
concentration of acetic acid (p<0.05) and butyric (p<0.05) acids, however, still showed 
prominent differences between DSS and non-DSS treated rats on experimental diets. See 
Appendix B for actual values. 
 
 
 
Relative concentrations were calculated for acetic and butyric acids as a relative 
percentage of total SCFA.  Baseline measurements reflect no diet effect on relative 
concentrations of acetic and butyric acids.  Following the final DSS exposure, 
differences were observed between DSS-treated rats and their non-DSS counterparts.  
DSS increased relative concentrations of acetic acid (p<0.05) and decreased relative 
concentrations of butyric acid (p<0.05) (Fig. 11).  After 2 wk of recovery following the 
final DSS treatment, animals fed a basal diet had comparable relative concentrations of 
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acetic acid between DSS and non-DSS treated rats.  Relative concentration of acetic acid 
(p<0.05) and butyric (p<0.05) acids, however, still showed prominent differences 
between DSS and non-DSS treated rats on experimental diets (Fig. 12).   
Increased concentrations of SCFA in the feces could be caused by an increased 
production or a decreased uptake, so expression of SCFA transport proteins SLC5A8 
and MCT-1 were measured.  In animals fed the basal diet, DSS significantly reduced 
expression of both SCFA transport proteins (p<0.05). Chlorogenic acid was able to 
partially mitigate the decrease in MCT-1 expression, while both quercetin and 
chlorogenic acid mitigated the DSS-induced decrease in SLC5A8 expression (Fig. 13). 
 
 
FIGURE 13 MCT-1 and SLC5A8 mRNA levels show that DSS significantly reduced 
expression of both genes in the basal diet (p<0.05).  Animals fed chlorogenic acid were 
able to mitigate DSS-induced decreases in MCT-1 expression.  Both experimental diets 
were able to mitigate DSS induced decreases in SLC5A8 expression. Means not sharing 
a common superscript are significantly different (p<0.05).  Data are LS means ±SEM, 
n=7-8 rats/diet.  See Appendix B for actual values. 
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Injury and injury repair 
Treatment with DSS significantly increased injury (p<0.0001) scores (Fig. 14).  
Non-DSS treated animals fed the chlorogenic acid diet had lower injury scores than non-
DSS treated animals fed the basal diet (p=0.0272).  Although diet did not have an effect 
on distal colon injury scores, bioactive compounds did alter expression of some injury 
repair molecules.  DSS-treated animals fed a quercetin diet had significantly higher 
expression of fibroblast growth factor-2 (FGF-2) than any other diet/treatment group 
(p<0.01) (Fig. 15).  FGF-2 is an injury repair molecule found on the basolateral 
membrane of epithelial cells.  In animals fed the quercetin diet, trefoil factor-3 (TFF-3) 
expression was lower in DSS-treated animals compared to non-DSS treated animals 
(p<0.05).  TFF-3 is a wound-healing molecule found on the apical membrane of colonic 
epithelial cells and is expressed predominantly by goblet cells (38).  A decrease in TFF-3 
expression could reflect impaired wound healing on the apical membrane of epithelial 
cells. Bioactive compounds did not mitigate DSS induced injury, however quercetin did 
beneficially alter expression of FGF-2. 
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FIGURE 14 DSS significantly increased injury score in all diet groups (p<0.0001).  In 
non-DSS treated animals, chlorogenic acid reduced injury score compared to the basal 
diet (p=0.0272).  Means not sharing a common superscript are significantly different 
(p<0.05).  Data are LS means ±SEM, n=7-8 rats/diet.  See Appendix B for actual values. 
 
 
 
 
FIGURE 15 Expression of injury repair molecules suggests that quercetin may be 
protective by increasing expression of basolateral repair molecule FGF-2 (p=0.0005).  
DSS-treated animals fed quercetin had lower levels of TFF-3 expression, an apical 
wound healing molecule (p=0.0035).  Means not sharing a common superscript are 
significantly different (p<0.05).  Data are LS means ±SEM, n=7-8 rats/diet.  See 
Appendix B for actual values 
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NF-κB activity and expression of downstream effectors 
DSS increased inflammation scores (p<0.01) in all diet groups (see Appendix B).  
However, NF-κB activity, a pro-inflammatory transcription factor, was not significantly 
increased by DSS (Fig. 16).  DSS-treated animals fed a chlorogenic acid diet had lower 
levels of NF-κB activity compared to those fed a basal diet (p<0.05).  Expression of NF-
κB-associated molecules was also measured in mucosal scrapings (Fig. 17).  In all diet 
groups, treatment with DSS resulted in significantly lower levels of RelA/p65 expression 
(p<0.05), the regulatory subunit of NF-κB.  In animals fed the basal diet, DSS-treatment 
also reduced expression of IκΒα expression, the molecule that prevents NF-κB 
translocation into the nucleus (p<0.05).  However, both experimental diets were able to 
mitigate the decrease in IκΒα expression.  
 
 
FIGURE 16 Chlorogenic acid significantly reduced NF-κB expression compared to the 
basal diet, in DSS-treated animals.  Means not sharing a common superscript are 
significantly different (p<0.05).  Data are LS means ±SEM, n=8-11 rats/diet.  See 
Appendix B for actual values. 
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FIGURE 17 DSS significantly reduced RelA/p65 mRNA levels in all diet groups 
(p<0.05). IκΒα mRNA levels were significantly reduced in DSS-treated animals fed the 
basal diet (p<0.05), but experimental diets maintained IκΒα mRNA expression. Means 
not sharing a common superscript are significantly different (p<0.05).  Data are LS 
means ±SEM, n=7-8 rats/diet.  See Appendix B for actual values. 
 
 
 
Expression of pro-inflammatory cytokines downstream of NF-κB was also 
measured (Fig. 18).  Contrary to what we expected, 2 wk after the last DSS treatment 
COX-2 expression in animals fed basal and quercetin diets was reduced (p<0.01) relative 
to the control rats.  Animals fed the basal diet had significantly higher levels of IL-1 
(p<0.01) and IL-12 (p<0.05) expression with DSS treatment.  Expression levels of COX-
2, IL-1, and IL-12 were not impacted by DSS treatment for animals fed chlorogenic acid 
diet.  IL-1 expression was also not impacted with DSS treatment for animals fed 
quercetin diet.  TNF-α, IL-6, and TGF-Β expression was not affected by either diet or 
DSS treatment (Table 2).  Given this data, DSS-induced inflammation may be directly 
impacted by IL-1 and IL-12 expression, two cytokines under the transcriptional control 
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of NF-κB, which can be mitigated in part by quercetin or almost completely by 
chlorogenic acid. 
 
 
FIGURE 18 DSS increased mRNA expression of IL-1 and IL-12 and reduced 
expression of COX-2 in animals fed the basal diet. Means not sharing a common 
superscript are significantly different (p<0.05).  Data are LS means ±SEM, n=7-8 
rats/diet.  See Appendix B for actual values. 
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TABLE 2 Expression of pro-inflammatory cytokines downstream of NF-κB1 
 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
 
Control DSS Control DSS Control DSS 
IL-6 752±168a 544±168a 923±168ab 1,365±180b 828±168a 606±168a 
TGF-Β 152±18a 147±18a 179±18a 177±20a 161±18a 170±18a 
TNF- α 1,804±354a 2,090±354ab 2,596±354ab 2,991±378b 2,543±354ab 1,662±354a 
1Values are LS means ± SEM.  Means not sharing a common superscript differ (p<0.05).  
n=7-8 rats/group. 
 
 
 
Toll like receptor pathways 
DSS reduced expression of TLR-4 in animals fed the basal diet, but did not 
significantly alter expression of TLR-2, TLR-9, and TLR-5 (Table 3).  Animals fed a 
chlorogenic acid diet had decreased expression of TLR-9 (p<0.01) with DSS-treatment, 
a potentially protective TLR.  Another protective TLR, TLR-2, had increased expression 
with quercetin supplementation in non-DSS treated compared to those consuming the 
basal diet (p<0.05). 
 
TABLE 3 Expression of TLRs, MyD88, and Tollip1 
 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
 
Control DSS Control DSS Control DSS 
TLR-2 3.9±1.0a 6.6±1.0ab 6.9±1.0b 7.7±1.7b 6.2±1.0ab 7.7±1.0b 
TLR-4 61.4±5.5a 30.3±5.5b 55.0±5.5a 34.9±5.9b 55.7±5.5a 36.5±5.5b 
TLR-5 30.1±3.6ab 25.3±3.6ab 31.2±3.6ab 22.7±3.8a 35.1±3.6b 26.1±3.6ab 
TLR-9 7.0±1.2abc 4.7±1.2ab 7.6±1.2bc 7.9±1.3bc 8.9±1.2c 3.9±1.2a 
MyD88 99.7±8.4c 60.4±8.4a 104.8±8.4c 70.5±8.9ab 91.8±8.6bc 74.2±8.4ab 
TOLLIP 58.1±4.2c 42.7±4.2a 57.0±4.2bc 45.1±4.4ab 56.7±4.2bc 46.8±4.2abc 
1Values are LS means ± SEM.  Means not sharing a common superscript differ (p<0.05).  
n=7-8 rats/group  
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 While some TLRs are thought to be protective, all TLRs activate NF-κB through 
MyD88 transduction molecules.  Treatment with DSS significantly reduced MyD88 
expression in basal and quercetin diets (p<0.05) (Table 3).  Tollip, a regulatory 
molecule, inhibits MyD88-induced activation of NF-κB.  Tollip expression was 
significantly reduced with DSS treatment in animals fed a basal diet (p<0.05) (Table 3).  
Chlorogenic acid maintained MyD88 expression levels with DSS treatment, while both 
quercetin and chlorogenic acid maintained Tollip expression levels.   
 
Tumor necrosis factor receptor pathways 
Although TNF-α expression was not affected by diet or treatment, TNFR 
expression was altered.  TNFR-1, the pro-apoptotic TNFR, expression was significantly 
reduced by DSS treatment in animals fed a basal diet (p<0.05) (Fig. 19).  However, 
animals fed quercetin and chlorogenic acid diets had comparable levels of TNFR-1 
between DSS and non-DSS treated animals.  In DSS-treated animals, RIP kinase (RIPk) 
expression was comparable across diets (See Appendix B).  Downstream effects of RIP 
include NF-κB activation and apoptosis via activation of caspase-8, -10, and -3.  This 
suggests that experimental diets may be able to maintain levels of TNFR-1-programmed 
cell death and/or necrosis.  TNFR-2 expression, which promotes cell survival and 
proliferation, was significantly increased by DSS treatment in animals fed quercetin 
(p<0.05).  
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FIGURE 19 DSS significantly reduced mRNA expression of TNFR-1 in animals fed a 
basal diet.  Quercetin and chlorogenic acid maintained expression of TNFR-1 
expression.  mRNA expression of TNFR-2 was elevated in DSS-treated animals on the 
quercetin diet. Means not sharing a common superscript are significantly different 
(p<0.05).  Data are LS means ±SEM, n=7-8 rats/diet.  See Appendix B for actual values. 
 
 
 
Proliferation in the distal colon 
No significant differences were observed with DSS treatment for proliferative 
zone (PZ), proliferative index (PI), or crypt height (CH) (Table 4).  DSS treated animals 
fed chlorogenic acid diet had shorter crypt heights compared to DSS-treated animals 
receiving the basal diet. 
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TABLE 4 Proliferation in the distal colon1 
 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
 
Control DSS Control DSS Control DSS 
CH 22.8±1.0ab 24.8±1.0b 20.9±1.0a 22.2±1.1ab 21.3±1.0a 21.9±1.0a 
PI 16.6±2.4ab 15.0±2.4a 20.0±2.4ab 20.0±2.7ab 22.2±2.4b 18.0±2.4ab 
PZ 39.0±2.5a 37.5±2.5a 41.3±2.5a 39.3±2.8a 43.8±2.5a 40.6±2.5a 
1Values are LS means ± SEM.  Means not sharing a common superscript differ (p<0.05).  
n=8-10 rats/group. 
 
Discussion 
Diets rich in fruits and vegetables are associated with a reduced risk of many 
diseases, including colon cancer and IBD (2, 3, 22).  Treatment regimens relying upon 
pharmaceuticals and biological therapies are currently inefficient in that they are often 
ineffective in approximately half of subjects (57).  Plums have been shown to have anti-
cancer (dried plums) and anti-inflammatory (plum phenolic extract) properties (23, 58).  
Quercetin and chlorogenic acid, found in stonefruits in high concentrations, have 
demonstrated anti-inflammatory properties in acute colitis (6, 7).  However, the ability of 
these bioactive compounds to combat chronic colitis has not been investigated.   
We used a chronic colitis model (3% DSS for 48 h, 2 wk separation, 3 cycles) to 
investigate the damaging effects of DSS and possible protective mechanisms of 
quercetin and chlorogenic acid.  The DSS-treated animals presented with symptoms 
similar to human UC: blood in the stool and diarrhea (increased fecal moisture content) 
(61).  Although weight loss is also a symptom of UC and a characteristic of acute colitis, 
the rats had no significant differences in weight throughout the study (65, 66).  Similarly, 
decreased intake is observed in acute colitis (66).  No decreases in intake were observed 
 49 
with DSS treatment, possibly due to the low dose of DSS used and that treatment only 
lasted 48 h.  Non-DSS treated animals fed quercetin consumed less than animals on the 
basal diet (Table 1).  Because intakes for other time points (wk 3 and 9) were not 
significantly different between diet and treatment groups, it is not apparent why this 
difference exists.  With the severity of the disease state observed (fecal observations) in 
DSS-treated animals, it was a unique observation to have comparable intakes between 
non-DSS and DSS treated animals.  
Changes in the microbial population (numbers, activities, distributions) is 
thought to be a contributing factor to UC (1).  Shifts toward more pathogenic bacteria or 
decreased production of beneficial molecules, like butyrate, could increase inflammation 
(32, 39). Diet has been shown to alter microbial populations and activities, and since 
chlorogenic acid and quercetin are metabolized by the microbiota, it is possible these 
bioactive compounds can influence the microbiota, as well as their fermentation patterns 
(51-53, 59).  However, experimental diets were unable to mitigate the DSS-induced 
increases in total SCFA concentrations.  Altered fecal concentrations of SCFA, including 
butyrate, have been reported in UC (39).  We observed an increase in SCFA 
concentrations with DSS treatment, suggesting that DSS did not inhibit fermentation 
rates of the microbiota.  During quiescent stages of UC, butyrate oxidation has reported 
to be normal (39).  Although we did not measure butyrate oxidation, slight decreases in 
butyrate concentrations during recovery phases (compared to active disease state) could 
indicate an enhanced uptake and/or utilization compared to active disease state.  
Although measuring SCFA concentrations in the feces provides a rough estimation of 
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fermentation patterns, fermentation should have been unaffected.  Since DSS causes 
injury and inflammation in the distal colon and fermentation occurs more extensively in 
the proximal colon, microbial populations in the proximal colon may not have been 
affected directly by DSS (42).  However, relative concentrations of butyrate and acetate 
shifted with DSS treatment, suggesting changes in microbial populations, fermentation 
patterns, or substrate uptake into epithelial cells.  Changes to the fermentation patterns 
could be a result of systemic inflammatory responses caused by the DSS.  Analysis of 
fecal samples from the proximal and distal colon collected at termination could provide 
more information on how fermentation rates are affected by colitis and by the dietary 
interventions.  In addition, microbial analysis of feces could provide more information 
on shifts in microbial populations.  Shifts in microbial populations could also alter 
fermentation products found in the lumen. 
Since fecal butyrate concentrations were elevated in DSS-treated rats, we 
assumed butyrate availability in the lumen was not limited for epithelial cells.  The high 
concentrations in the feces could be due to a decreased expression of MCT-1 and 
butyrate uptake, which has already been demonstrated in DSS-induced colitis (55).  
Mitigation of DSS-induced decreases in MCT-1 expression by chlorogenic acid and in 
SLC5A8 expression by both bioactive compounds suggests that uptake may not have 
been impaired, however it would be necessary to document protein levels by Western 
blot or immunohistochemical techniques to determine if levels of the transport proteins 
were maintained.  
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Butyrate is thought to have anti-inflammatory and anti-cancer properties (39).  
Although butyrate concentrations and butyrate transport protein expression were not 
decreased in DSS-treated animals on experimental diets, there was no diet effect on 
injury or inflammation score.  Likewise, both quercetin and chlorogenic acid derivatives 
have been shown to have anti-inflammatory properties, but no change was observed in 
injury or inflammation score in our study (6, 7).  DSS did significantly increase 
epithelial injury and colonic inflammation, which mimics human UC (1, 61).  The 
severity of the three exposures to DSS could have caused damage too extensive for 
experimental diets to compensate for.  In addition, hydrocaffeic acid demonstrated to be 
an anti-inflammatory in an acute model that used cellulose as its fiber source (7).  While 
this acute model used a higher DSS dose (4%), it only had one treatment instead of 
three.  In addition, cellulose in the diet may limit DSS interaction with the epithelium, 
since it is a non-fermentable fiber and reaches the distal colon, whereas the fermentable 
fiber pectin used in the current study would have been extensively fermented within the 
proximal colon.  However, gene expression data did suggest that quercetin and 
chlorogenic acid might function to enhance injury repair molecules and suppress 
inflammation pathways.  
Quercetin also has been shown to enhance epithelial barrier function in vitro by 
increasing expression of claudin-4, a tight junction protein (25).  Injury repair molecules 
can play an important role in maintenance of the epithelial barrier in UC, as well. A 
decrease in TFF-3, an apical wound-healing molecule, was observed with DSS-treatment 
in animals fed a quercetin diet.  Since TFF-3 is also an injury repair molecule, this is not 
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considered beneficial. TFF-3 is expressed by goblet cells, suggesting a decrease in 
number or function of goblet cells in animals fed quercetin (38).  Although apical injury 
repair may be impaired in those fed a quercetin diet, quercetin could enhance wound 
repair by rebuilding the tissue from the basolateral membrane through enhanced 
expression of FGF-2.   Due to the extensive damage to the epithelium and high levels of 
fecal moisture content (diarrhea), goblet cells could have decreased in number or 
function, reducing the level of TFF-3 expression.  However, due to the extent of the 
injury caused by DSS, injury repair deeper in the tissues may be more important than 
apical repair. 
Proliferation is also necessary for maintenance of the epithelial barrier.  Previous 
studies of acute colitis showed that proliferation was increased during the active state of 
disease (65).  Hyper-proliferation, in conjunction with inflammation, can lead to tumor 
formation (27).  Since our animals were terminated during a period of remission, 
proliferation levels (proliferative index and proliferative zone) were comparable across 
diet and treatments.  If animals were terminated during an active state of disease, 
changes in proliferation due to diet and/or treatment may have been observed. 
Bioactive compounds did affect pathways that regulate the cell cycle.  Quercetin 
and chlorogenic acid mitigated DSS-induced decreases in TNFR-1 expression.  In 
addition, quercetin reduced expression of TNFR-2 in DSS-treated animals. Through RIP 
and caspase-8, TNFR-1 is able to induce cell death (34). TNFR-2 also plays a role in the 
cell cycle during inflammation, although it is responsible for cell proliferation and 
survival, rather than cell death (31). TNFR mRNA expression data would suggest that 
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DSS-treated animals on a quercetin diet would have decreased levels of proliferation, 
although these changes were not observed.  Despite the changes in TNFR expression, we 
cannot conclusively discuss downstream changes.  Western Blot or 
immunohistochemical methods could elucidate protein levels of TNFR-1 and -2.  In 
addition, TNFR must be stimulated by TNF-α or other ligands in order to trigger 
downstream biological responses (34).  Our study showed no increase with diet or DSS 
treatment in TNF-α expression, which could be the reason why no change was observed 
in proliferation rates.   
Both TNFR-1 and -2 also function to activate NF-κB, which is not only anti-
apoptotic, but also promotes expression of pro-inflammatory cytokines (31).   NF-κB is 
also activated through TLR pathways and MyD88 transduction molecules (21, 30).  
Chlorogenic acid significantly decreased NF-κB activation in DSS treated animals when 
compared to the basal diet.  When evaluating the effect of chlorogenic acid on NF-κB-
related expression, we observed maintenance of IκΒα, MyD88, and Tollip expression.  
Quercetin mitigated DSS-induced decreases in Tollip and IκΒ expression. Since 
dysregulation in NF-κB activation occurs in UC, chlorogenic acid and quercetin may be 
able to maintain regulation of NF-κB activation by suppressing DSS-induced changed in 
NF-κB regulatory molecules.  Proper regulation of NF-κB in epithelial cells could be 
protective in colitis (2, 27, 32).   
Due to the high level of inflammation in chronic colitis, an elevation in NF-κB 
was expected.  The elevation in NF-κB activity in the basal diet with DSS treatment was 
not significant.  Expression of NF-κB-associated molecules (RelA/p65 and IκΒα) was 
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reduced by DSS treatment, however.  The reduced expression of NF-κB could be why 
NF-κB activation was not elevated as we expected.  Downstream of NF-κB, expression 
of pro-inflammatory cytokines was affected by both diet and treatment.  DSS-treated 
animals on the basal diet showed increases in IL-1 and IL-12. Quercetin has been shown 
to inhibit inflammation in acute DSS-induced colitis by suppressing NF-κB activation 
(6).  Quercetin was able to mitigate DSS-induced increases in IL-1, a severe pro-
inflammatory cytokine and activator of NF-κB. Hydrocaffeic acid, has also shown to 
alleviate DSS-induced inflammation in acute colitis by suppressing expression of pro-
inflammatory cytokines (7). In our study, expression levels of COX-2, IL-1, and IL-12 
were comparable between non-DSS and DSS treated animals on the chlorogenic acid 
diet.  Quercetin and chlorogenic acid may function through TLR and NF-κB pathways to 
influence expression of pro-inflammatory cytokines. 
Although elevated COX-2 levels were expected with DSS treatment, reduced 
levels of COX-2 were actually observed.  COX-2 can promote inflammation and 
tumorigenesis, but can also be protective when expressed in epithelial cells (27).  COX-2 
may contribute to the decreased paracellular permeability to bacterial translocation into 
the lamina propria (27).  The reduced expression of COX-2 with DSS treatment in 
animals fed basal and quercetin diets could be harmful, especially since dysbiosis and 
impaired integrity of the epithelium occurs in UC.  Quercetin did reduce COX-2 
expression in non-DSS treated animals, as occurred in a prior experiment using the 
AOM model of colon cancer (15). 
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Conclusion 
The ability of quercetin and chlorogenic acid to down-regulate expression of pro-
inflammatory cytokines may not be the only mechanism of protection in UC.  Altering 
the luminal environment and uptake of SCFA, in addition to enhancing injury repair 
molecule expression could protect the epithelium in colitis.  These compounds could 
also impact the cell cycle, although no difference was observed in proliferation.  Further 
studies should be completed to examine these compounds during the different stages of 
colitis.  More significant differences could have been observed if animals were 
terminated immediately following the third DSS exposure, for example.  We did not 
choose this termination time point due to the severity of the disease state and the thought 
that, at that time, there would be little or no intact mucosa.  Also, if given a longer 
recovery period these bioactive compounds could have continued to function through the 
previously described pathways to induce a more rapid recovery.  Staggering termination 
time points would reveal the most conclusive data to how quercetin and chlorogenic acid 
prevent injury and inflammation and enhance injury repair.  Lastly, further studies 
should examine these compounds in levels comparable to those found in Western and/or 
Mediterranean diets.  These compounds could also be examined together in order to 
identify any additive or synergistic effects.  Our data suggests potential benefits of 
supplementing the diet with foods rich in quercetin and chlorogenic acid, like 
stonefruits. However, further investigation is needed before this data can be translated to 
clinical trials.
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CHAPTER III 
SUMMARY AND CONCLUSIONS 
 
Summary 
 
Pharmaceuticals and biological therapies for ulcerative colitis (UC) are currently 
inefficient in that they are often ineffective in approximately half of subjects (57).  
Dietary interventions increasing the amount of phytochemical-rich fruits and vegetables 
are associated with a reduced risk of many diseases, including colon cancer and IBD (2, 
3, 22).  A diet rich in phytochemicals, like quercetin and chlorogenic acid, is thought to 
be protective due to their anti-cancer, anti-oxidant, and anti-inflammatory properties.  In 
chronic inflammatory diseases, reducing inflammation can not only alleviate symptoms, 
but also protect against carcinogenesis.  Proper regulation of the cell cycle is also 
important for maintenance of the epithelial barrier, wound healing, and prevention of 
hyperplasia.  Previous studies have elucidated possible mechanisms by which quercetin 
and chlorogenic acid function in vitro and in vivo, but only in acute colitis models. 
Inflammation associated with UC and DSS-induced colitis is controlled through 
the NF-κB pathway.  Although NF-κB activity was not significantly increased by DSS in 
animals fed the basal diet, DSS treatment reduced expression of NF-κB subunits and 
regulatory molecules (RelA/p65, IκΒα, MyD88, Tollip).  The reduced expression of NF-
κB and related molecules could be why NF-κB activation was not elevated.  To verify 
the reduction in NF-κB activation is caused by a reduced expression of NF-κB-associated 
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molecules, protein levels could be measured.  Altered levels of expression of these 
molecules could suggest a dysregulation of NF-κB activation, which can exacerbate NF-
κB-mediated inflammation.  This study showed that quercetin maintains Tollip and IκΒα 
expression and chlorogenic acid maintains expression of MyD88, Tollip, and IκΒα.  This 
suggests that quercetin and chlorogenic acid may preserve the healthy regulation of NF-
κB activation.  MyD88 and Tollip are involved in TLR pathway.  With DSS treatment, 
we did not observe increased expression of TLR.  On the contrary, TLR-4 expression 
was decreased by DSS treatment.  Increased levels of TNF-α have shown to increase 
expression of TLR-4 in vitro (37).  Since TNF-α expression was not altered, this could be 
the reason an increase in TLR-4 expression was not observed. 
Downstream of NF-κB, elevated expression of pro-inflammatory cytokines (IL-1 
and IL-12) was observed with DSS exposure in animals fed the basal diet.  IL-1 
stimulates further activation of NF-κB through positive feedback and also injures the 
protective mucosa (20). Quercetin was able to mitigate DSS-induced increases in IL-1, 
while chlorogenic acid mitigated DSS-induced changes in expression of COX-2, IL-1, 
and IL-12. By suppressing expression of IL-1, quercetin and chlorogenic acid may have 
been able to inhibit NF-κB activation and maintain NF-κB regulation. 
While NF-κB could exacerbate inflammation through increased activity in 
macrophages, activated NF-κB could play a protective role by promoting cell repair and 
integrity of the epithelial barrier (1, 20, 21).  Since the mucosal scrapings contain a large 
portion of epithelial cells, the decreased activity of NF-κB observed could reflect an 
inhibition of protective mechanisms, as well.  For example, reduced levels of COX-2 
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expression were observed with DSS treatment in animals fed a basal diet. In epithelial 
cells, COX-2 expression limits bacterial translocation into the lamina propria (27).  
Allowing for increased permeability of the paracellular pathways could exacerbate 
immune and inflammatory responses.  Quercetin, the positive control diet, did reduce 
COX-2 expression in non-DSS treated animals, as previously demonstrated in an AOM 
model (15). 
Other protective mechanisms include SCFA transport, TLR-mediated protection, 
and enhanced expression of injury repair molecules. Quercetin increased TLR-2 
expression, a molecule that has downstream anti-inflammatory effects (increased TFF-3 
expression) (38, 39).  TFF-3, an apical injury repair molecules was decreased in DSS-
treated animals fed the quercetin diet.  This indicates that increased TLR-2 expression 
does not necessarily reflect TLR-2 stimulation.  Quercetin may enhance wound healing, 
however, through increased expression of FGF-2, a basolateral membrane repair 
molecule.  In addition, chlorogenic acid may be protective in a non-colitis state.  
Although the mechanism is unclear, chlorogenic acid reduced injury score in non-DSS 
treated animals. 
Lastly, sufficient energy sources (i.e. butyrate) are needed for a proper 
functioning epithelium.  DSS increased butyrate concentrations in the feces, but no diet 
effect was observed.  The increased SCFA concentrations in the feces could be due to an 
increased production and/or a decreased uptake.  In addition, changes in the relative 
concentrations of SCFA could be due to changes in bacterial populations.  Chlorogenic 
acid was able to mitigate the DSS-induced decreases in both MCT-1 and SLC5A8, while 
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quercetin only showed benefit for SLC5A8 expression.  These bioactive compounds may 
preserve SCFA transport that is usually impaired in UC. 
 
Conclusions 
 
The involvement of these compounds in inflammatory, substrate transport, and 
injury repair pathways could elucidate specific protective mechanisms and provide 
further support that a diet rich in phytochemicals can be not only beneficial to reduce 
cancer risk, but also to alleviate inflammation in UC.  Quercetin may enhance wound 
healing (FGF-2) and maintain levels of SCFA transport (SLC5A8), while functioning as 
an anti-inflammatory (IL-1).  Chlorogenic acid may maintain levels of SCFA transport 
(SLC5A8 and MCT-1) and function as an anti-inflammatory (IL-1 and IL-12), as well.  
Both compounds may have the ability to prevent dysregulation of NF-κB pathways 
through maintenance of RelA/p65, MyD88, Tollip, and IκΒα expression.  Together, in 
stonefruits, these compounds could target multiple protective mechanisms.  However, 
these mechanisms should be further investigated by measuring protein levels in the 
epithelial cells.  
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Future Research 
 
Results from this study provide merit for further investigation of supplementing 
the diet with foods rich in quercetin and chlorogenic acid.  While quercetin and 
chlorogenic acid affected expression of some of the same molecules, they also had 
unique effects.  If these compounds were studied together in one diet, it is possible they 
could have additive or synergistic effects.  In order to study these compounds together in 
one diet, it would also be necessary to use levels more reflective of those found in the 
Western and/or Mediterranean diets. Since chlorogenic acid was effective at a low dose, 
there is potential that chlorogenic acid could have mitigated injury and inflammation 
scores at a higher concentration.  Since quercetin levels were extremely high, a lower 
dose should be investigated, to see if protective mechanisms are still active at lower 
doses.   
Our study suggests that quercetin and chlorogenic acid may play a role in both 
NF-κB and TLR pathways.  However, in order to form a confident conclusion of which 
pathways are impacted by these compounds, further analysis of gene expression and 
protein levels is needed.  In addition, some of the expected outcomes (increased NF-κB 
activation and COX-2 expression) were not observed.  Since these outcomes were 
observed in acute colitis, altering the experimental design could reveal more prominent 
changes in inflammatory pathways.  This could be achieved by staggering termination 
points.  For example, terminating animals in order to obtain tissue samples during active 
disease state and throughout the recovery process.   
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Although this study showed no diet effect on injury and inflammation scores, 
gene expression data suggests that quercetin and chlorogenic acid may have benefits if 
supplemented in the diet.  However, further investigation of the additive and synergistic 
effects of these compounds during active colitis and recovery periods is necessary before 
these results can be translated to clinical trials. 
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APPENDIX A 
EXPERIMENTAL PROTOCOLS 
 
 
Preparation of Diets 
 
Weighing/Preparing diet components  
 
Goals:     
1. Measure diets into appropriate tubs and freezer bags 
2. Arrange in order 
3. Seal and store in freezer, if necessary 
4. Record diet lot numbers 
5. Document process and take pictures 
 
Supplies:  
1. Make sure there are adequate diet components 
2. Test compounds (Quercetin anhydrase, Q4951-10G, Sigma; Chlorogenic acid 
min. 95% titration, C3878-5G, Sigma) 
3. Adequately clean and label tubs and freezer bags for diet components 
Tub specs: contains up to 20 kg of diet 
Gallon sized Ziploc bags and outer bags 
4. Arrange manpower 
5. Weighing scales (2): 50 g-5 kg and >50 g 
6. Measuring tubs and scoops (& spatulas) 
7. Stirring tool 
8. Adequate labeled diet bags and outer bags 
9. Colored tapes 
10. Sharpies 
11. Aluminum foil 
12. 5 L jugs for oil (2-3) 
13. Cart, tub for ice, and ice 
14. Gloves, bench papers, napkins 
15. Diet specification sheets 
16. Mixing bowl and mixer (2) 
17. Labeled vials and specimen cups for diet samples 
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Location: Kleberg basement (diet mixing room) 
Manpower: At least 2 
 
Procedure: 
1. Transport diet components from storage and/or freezer to mixing room 
2. Bring supplies to mixing room 
3. Weigh out diet components (according to specification sheet) in the following 
order 
1st—Dextrose (tub) 
2nd—Casein (tub) 
3rd—Pectin (tub) 
4th—Mineral mix | 
5th—Vitamin mix | all in 
6th—Methionine  | one tub 
7th—Choline* |  
4. Arrange tubs that belong to a diet group together; within diet groups, arrange 
into bowl number 
5. Store tubs containing mineral/vitamin/methionine/choline mix in freezer 
6. Record diet lot numbers 
7. Seal, label, and store any excess diet components 
8. Clean up 
*Note: Choline is kept in a desiccator because it absorbs moisture easily.  It will only be 
taken out when it is time to measure choline.  Once measured, the choline needs to be 
mixed in with the salt/vitamin mix to ensure dryness. 
 
Diet Component Company Catalog Number Lot Number 
Corn Oil NF DYETS 401150 14058 
Dextrose Harlan 160190 08157 
Casein- High Protein Harlan 160030 08088 
DL-methionine Harlan 10850 08046 
Vitamin Mix, AIN-76A Harlan 40077 255073 
Mineral Mix, AIN 76 Harlan 170915.pwd 255578 
Pectin ISS 150 Citrus (Coyote) Gum Tech 68779 08G3F001Z 
Choline bitartrate Harlan 30190 08258 
Quercetin anhydrase Sigma Q4951-10G 118K0888 
Chlorogenic acid min. 95% titration Sigma C3878-5G 127K640 
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Mixing diets 
Goals: 
1. Measure oil needed for the day 
2. Mix diet components into each diet groups 
3. Package and double-seal into freezer bags 
4. Store diet bags in freezer 
5. Document process and take pictures 
 
Supplies: (see Preparing/weighing diet components) 
 
Start time: 8am 
 
Location: Kleberg basement (diet mixing room) 
 
Manpower: at least 4 
 
Procedure: 
1. Get cart, 2-3 5 L jugs, tub big enough to fit jugs and ice, aluminum foil, bench 
papers, scissors, sharpies, napkins, weigh scale, plastic beaker. 
2. Go to Dr. Chapkin’s lab to measure out corn oil, where it is also stored.  
When done, fill remaining barrel of oil with nitrogen gas, seal, date, and store 
back in freezer.  Record lot number. 
3. Cover jugs with foil, label, and put on ice. 
4. Bring 2 big stainless steel mixing bowls from lab to basement. 
5. Measure out test compounds, add to mineral/vitamin, methionine/choline mix 
and mix well. 
6. Start with Bowl 1 of a diet group, mix by hand diet components in the 
following sequence: 
1st—Pectin 
2nd—Mineral/vitamin/methionine/choline mix (this mix was prepared day 1) 
(if experimental diet, mineral mix should have quercetin or chlorogenic acid 
already mixed in Step 5) 
3rd—Casein  
4th—Dextrose  
7. Fit bowl onto electric mixer, cover, and mix dry components for 5 min at #1 
setting. 
8. Still at setting #1, start mixer for 10 min.  During this time, pour oil into mix 
in 3 separate quantities and times.  To get all oil out from jug, use diet to mop 
it up. 
9. Scrape sides of bowl and blade, mix for 5 min more. 
10. Lower bowl, scrape sides of bowl and blade.  Put bowl back into position and 
mix for 10 min at #2 setting. 
11. Scrape diet off blade, lower and remove bowl.  Take a sample of diet mix 
from four locations in the bowl (send off to analysis). 
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12. Scoop diet into labeled bags and double-bag.  Store in labeled plastic tubs in 
freezer. 
13. Repeat above diet process for all diet groups. 
14. Clean up. 
Notes:  
 Before starting on a new diet group, remember to wash bowls and scoops, and 
change gloves to prevent cross-contamination. 
 
 Bowls and scoops need to be sprayed with 70% EtOH after washing and drying. 
 
 The dry diet components are in powder form so dust clouds form when pouring; 
pour slowly to reduce dust. 
 
 Mineral mix, vitamin mix, and methionine are stored in the freezer, so put back in 
freezer after measuring out into tubs. 
 
 The mineral/vitamin/methionine/choline mix might be lumpy, so it is best to use 
gloved hands to break up the lumps and mix uniformly. 
 
 Diet samples are taken after mixing for analysis of composition.  The small vials 
are used to collect samples throughout the feeding period and at the end. 
 
Diet component Basal Diet Quercetin Diet Chlorogenic acid diet 
Dextrose 51.06% 50.61% 51.01% 
Casein 22.35% 22.35% 22.35% 
DL-methionine 0.34% 0.34% 0.34% 
Mineral mix 3.91% 3.91% 3.91% 
Vitamin mix 1.12% 1.12% 1.12% 
Choline bitartrate 0.22% 0.22% 0.22% 
Pectin 6.00% 6.00% 6.00% 
Lipid-corn oil 15.00% 15.00% 15.00% 
Quercetin - 0.45% - 
Chlorogenic acid - - 0.05% 
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Tissue collection at termination 
 
Termination 
Rats were euthanized by CO2 asphyxiation followed by cervical dislocation, and 
disruption of the diaphragm through a midline incision.  The colon is resected, fecal 
contents removed and rinsed with PBS. Then two 1 cm sections are removed for 
histological preparations and the remainder is scraped for mucosa.  See below for tissue 
and sample preparation and storage. 
 
4% PFA Solution 
PFA solution was mixed a day before the killing.  50 ml of 10X PBS was diluted to 400 
ml with ddH2O, and then 200 mL of 20% PFA was added. PFA solution was 
refrigerated. 
 
Cassetting 
Before starting, put a small specimen cup (150 mL) with PFA solution (80 mL) (see 
above) in an ice bucket. Put 80 mL 70% EtOH in another small specimen cup (150 mL).  
Work first with the colon tissue that is in the PFA weight boat.  Take the colon tissue 
with tweezers from the external side of the tissue (be very careful to touch it minimally 
and try not to touch the mucosa side of the tissue) and place it on the sponge in the PFA 
cassette; the mucosa side should be exposed.  Stretch the tissue with the tweezers, trying 
not to damage the mucosa side.  Close the cassette and place it in the cup with PFA 
solution.  Start timer for 4 hours.  Take the colon tissue from EtOH weight boat and do 
the same as the PFA, but place it in the 70% EtOH cup. 
 
PFA/EtOH changing solutions for PFA fixed tissues 
Place the cassette with the colon tissue in PFA solution and start timer for 4 hours.  After 
this time, rinse the cassette with 50% EtOH and place it again in the cup filled with 50% 
EtOH.  Change EtOH solution every 20 minutes.  After the 4th change of 50% EtOH, use 
70% EtOH for 3 changes.  Refrigerate the cup after the last solution change. 
 
Mucosal scrapings and mRNA sample preparation 
After fecal material was removed from each colon (proximal and distal), it was washed 
twice with RNase free Phosphate Buffered Solution (PBS).  Mucosa was scraped from 
the colon on an RNase free surface (on ice) and transferred to an RNase free 
homogenization tube along with 500 µL of Denaturation solution (Ambion).  Scraped 
mucosa was homogenized for at least six strokes and then transferred to a 2 mL eppitube 
for storage at -80°C. 
 
 
Mucosal scrapings and protein aliquots preparation 
Scraped mucosa was placed into a homogenizer along with 400 µL of buffer (see below), 
homogenized for at least 7 strokes (on ice) and transferred into a 2 mL eppitube.  The 
sample was aspirated through a 23-gauge needle twice then incubated on ice for 30 min 
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prior to centrifugation at 15,000 g for 20 min. The supernatant was transferred and the 
volume split among aliquot tubes, then placed in a -80°C freezer for storage. 
 
Protein buffer 
Protein buffer (10 mL) was mixed on the day of the kill, just prior to use.  The protein 
buffer contained: 1 mL 500 mM Tris-HCl (pH 7.2, Sigma, T1503), 2.5 mL of 1.0 M 
sucrose (Sigma, S9378), 100 µL 200 mM EDTA (pH 7.6, Sigma, ED4SS), 100 µL 100 
mM EGTA (pH 7.5, Aldrich, 23453-2), 1.25 µL 0.4 M NaF (Sigma, S6521), 4.554 mL 
H2O, 1 mL 10% Triton X-100 (Sigma, T6878), 100 µL 10 mM orthovanadate (Sigma, 
S6508), 400 µL Protease Inhibitor (Sigma, P8340). 
 
Scoring for Injury and Inflammation  
PFA fixed tissues were stained with H&E and scored for injury and inflammation by a 
pathologist (63). 
 
Inflammation Score 
0: presence of occasional inflammatory cells in the lamina propria  
1: increased numbers of inflammatory cells in the lamina propria 
2: confluence of inflammatory cells, extending into submucosa 
3: transmural extension of the infiltrate  
 
Epithelial Injury Score 
0: no mucosal damage 
1: discrete lympho-epithelial lesions 
2: surface mucosal erosion or focal ulceration  
3: extensive mucosal damage and extension into deeper structures of the bowel wall  
 
Fecal Dry Matter Protocol 
 
1. Label aluminum pans.  Use pressure tool (burnisher) to “carve” number on tab. 
2. Dry pans in oven at 60°C over weekend. 
3. Remove pans from oven using tongs and place in a desiccator to cool.  The pans may 
be stacked for storage. 
4. Never touch the pans with hands.  Use only tongs or forceps. 
5. Remove one pan at a time, weigh, and record the weight of each pan. 
6. Weigh the pellet(s) in each pan, keeping a written record of which animal # 
corresponds with each pan. 
7. Dry fecal material for 72 h and 60°C. 
8. Move the pans with dried pellets to the vacuum desiccator.  Remember to use tongs 
and do not stack the tins. 
9. Allow samples to cool in vacuum desiccator overnight. 
10. Move pans and pellets to plain desiccator one at a time with tongs.  Do not stack. 
11. Weigh and record each sample, one at a time. 
12. Return pans with pellets to 60°C over for overnight. 
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13. Repeat steps 8-11 until pellets weigh the same as the previous weight recorded. 
 
 
 
PCNA methodology 
 
 
Adapted by Leigh Ann Piefer (finalized May 17, 2011) 
Protocol completed by Dr. Andy Ambrus (Texas A&M, Vet Med, WO#10468) 
 
1.  Deparaffinize slides 
 xylene---------------5 min  (3 times) 
[allow slides to dry and circle sections with pap pen] 
 100% EtOH--------5 min (2 times) 
 95% EtOH---------3 min (2 times) 
 70% EtOH---------3 min 
 distilled H2O ---------------3 min 
 
 Place citrate buffer (Reveal Decloaker) in a plastic coplin jar.  Using a water bath, 
heat citrate buffer to 97° C.   
 Leave slides in citrate buffer for 45 minutes. 
 Remove coplin jar and cool for 20 minutes at room temperature. 
 >>Transfer slides to ddH2O for 3 minutes 
 
2.  Remove endogenous peroxidase activity 
 3% H2O2 for 30 min 
 20 mL of 30% H2O2 +180 mL methanol 
 
3.  Wash in PBS  
 5 min, 3 times. 
 
4.  Prepare Vectastain Blocking Serum by adding  
 3 drops of stock Normal Serum (yellow label) to 10 mL of PBS in yellow mixing 
bottle. 
 
5.  Cover each section with Vectastain Blocking Serum.  Let stand for 20 min.  
 Save remaining Vectastain Blocking Serum for step 9. 
 
6.  Wash with PBS  
 Cover each section with PBS, 2 min, 3 times 
 
7.  Add anti-PC10 (1:100) to each section, completely covering each section (~200 µL).  
For the negative control slide use PBS instead of anti-PC10.  Let stand for 1 hour. 
% dry matter= g dry wt/ g wet wt * 100% 
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8.  Wash with PBS  
 Cover each section with PBS, 2 min, 3 times 
 
9.  Prepare Vectastain biotinylated anti-mouse IgG.  
 Add 25 µl of stock biotinylated antibody to 5 ml of serum solution from step 4, 
Mix Gently. 
 
10.  Cover each section with Vectastain biotinylated anti-mouse IgG.  Let stand for 45 
min.   
 
11.  Prepare ABC reagent in advance to be used in step 13.  The ABC reagent is prepared 
by adding  
 -2 drops of reagent A (gray label) to 5 ml PBS in the ABC Reagent gray mixing 
bottle.   
 - Mix gently. 
 -Add exactly 2 drops of Reagent B (gray label) to the same mixing bottle,  
-Mix immediately, and allow ABC Reagent to stand for about 30 minutes before 
use.   
*This should be done in a darkened area. 
 
12.  Wash with PBS  
 Cover each section with PBS 
 2 min, 3 times 
 
13.  Apply Vectastain ABC reagent that has been prepared in step 11.  Cover each 
section and let stand for 30 min. 
 
14.  Wash with PBS   
 2 min, 3 times 
 
15.  Prepare DAB solution 
 Place 5.0 mL of distilled deionized water in a 15 mL tube 
 Add 2 drops of Buffer Stock Solution and mix well 
 Add 4 drops of DAB Stock Solution and mix well 
 Add 2 drops of Hydrogen Peroxide Solution 
 
16.  One slide at a time, cover sections with DAB solution.  Incubate until staining 
develops (approximately 50-60 s).  Rinse with ddH2O and place in distilled deionized 
water. Repeat for each slide. 
 Discard DAB solution and initial rinse water into hazardous waste bottle. (DAB 
is a mutagen). 
 
17.  Wash with ddH2O for 5 min. 
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18.  Deactivate all DAB materials (glassware, pipet tips, used stock vials, stir bars) and 
used DAB solutions with bleach overnight, and flush with excess water in drain next day 
(20 minutes) 
 
19.  Counterstain with filtered Hematoxyline  < 1 sec. 
 
20.  Rinse with H2O briefly to remove excess counterstain, then wash with H2O 4 min, 1 
times. 
 
21.  Dehydrate slides: 
 1 x 1 min 70% EtOH. 
 1 x 1 min 95% EtOH. 
 1 x 1 min 100% EtOH. 
 3 x 2 min Xylene. 
 
22.  Apply permount and cover glass.  Use the wet mounting method. Work quickly to 
keep tissues moistened.  Apply slight pressure to remove any air bubbles. 
 
23.  Allow slides to dry over night before cleaning with xylene and examining at 40x. 
 
Reagents: 
 
1.  Phosphate buffered saline (PBS) 
2.  Vectastain ABC Elite Kit -- mouse IgG 
 source: Vector Lab. 
 Cat #: PK-6102, 1 ml/ea. 
 contains: blocking serum 
 biotinylated antimouse IgG 
 avidin-biotin complex 
3.  PCNA monoclonal antibody, Purified 
 source: COVANCE Signet lab 
 Cat #: SIG-3523, 1ml/ea 
4.  Diaminobenzidine or DAB Substrate Kit for Peroxidase 
 source: Vector 
 Cat #: SK-4100 
5.  Harris hematoxylin 
 Source: Sigma-Aldrich 
 Cat#: HHS 
6. Reveal Decloaker 
 Source: BioCare Medical 
 
Critical steps prior to staining: 
1.  tissue fixation in 70% ethanol. 
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2.  processing and baking of tissue at temperatures not exceeding 50° C. 
3.  keep slides moist at all times during the staining procedure. 
4.  include one positive and one negative control slide in each batch of slides stained. 
 
 
 
Mucosal mRNA Isolation 
 
 
Totally RNA Kit (Applied Biosystems #AM1910) 
**Tissue must be removed using RNase free conditions.  All disposables, glassware and 
reagents must be RNase free.** 
1. Measure and record volume of lysate (200-250 uL) 
2. Bring all volumes of lysate up to 500 µL using Denaturation Solution (Applied 
Biosystems, AM 8540G) FLICK tubes to mix 
3. In hood, add 1 ½ vol. (starting volume= 500 uL) (750 uL) phenol/CHCl3 :IAA 
(lower phase) (use fresh tip each time) 
4. Shake vigorously for 1 min.; store on ice for 5 min.   
5. Prepare Heavy PLG tubes by centrifuging for 30 s at 14000 X g @ 18-20ºC (face 
joint outwards) 
6. Transfer everything to prepared Phase Lock Gel Tube (Heavy 2 mL, version- Cat 
# 2302830) 
7. Centrifuge 16,000 x g, 5 min., 18-20°C 
8. Use one tip to “clear” the top milky layer of contaminants 
9. Transfer upper phase to new 2.0 ml eppitube. If there is no supernatant add 250 
µL more of phenol/CCH3 :IAA and re-centrifuge 
10. Add 1/10 vol. (~40-45 uL) sodium acetate; (Remember to check approx. vol.) 
Mix by shaking or inversion for about 10 s 
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11. Add 1 vol ACID: phenol/CHCl3 #2  (Starting volume=500 uL). Do not add more 
than one starting volume even if the volume of the lysate is greater than the 
starting volume (lower phase=remember new tips) 
12. Shake vigorously for 1 min.; store on ice for 5 min. 
13. Prepare Heavy PLG tubes by centrifuging for 30 sec at 14000 X g @ 18-20ºC 
(face joint outwards) 
14. Transfer to new Phase Lock Gel tube (Heavy 2 mL version- Cat # 2302830) 
15. Centrifuge at 16,000 x g, 5 min at 18-20°C 
16. Transfer upper phase to new tube 2.0 mL eppitube 
17. Measure and record the volume (~300 uL) 
18. Add an equal volume (measured in previous step) isopropanol; mix well (invert 
or flick) 
19. Store at -20°C, at least 30 min. to overnight  
20. Centrifuge at 14,000 x g, 15 min. at 4°C.  Discard supernatant (pour off into 
phenol waste) 
21. Wash pellet with 300 µL of 70% ethanol; flick for ~0.5-3 min 
22. Centrifuge for 5-10 min at low speed  (~3000 X g or 7,500 rpm in a microfuge) at 
RT or 4°C.  Discard supernatant 
23. Wash pellet with 300 µL of 70% ethanol; flick for ~0.5-3 min 
24. Centrifuge for 5-10 min at low speed  (~3000 X g or 7,500 rpm in a microfuge) at 
RT or 4°C 
25. Carefully remove supernatant with pipette and discard.  Respin briefly, remove 
supernatant with fine tip pipette. 
26. Cover w/ Kim wipe and air dry for ~ 5 min. 
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27. Re-suspend mRNA pellet in 50 µL Nuclease Free Water (Applied Biosystems, 
AM9937)  
28. Heat to 55° for ~8 min and vortex occasionally for all mRNA to go into solution. 
 
DNase treatment: 
1. To mRNA, add 0.1 vol (~5 uL) 10X DNase I buffer (Ambion DNA free kit, 
Applied Biosystems, AM1906) and 2 µL DNase.  Mix gently and incubate at 37°C 
for 20-30 min.   
2. Add 0.1 vol (~5 uL) DNase inactivation reagent (after resuspending it).  Incubate at 
RT for 2 min, flicking a few times during incubation.   
3. Centrifuge tube  ~1.5 min 10,000 g 4°C.  Remove supernatant to new tube, leaving 
reagent behind.  
4. Place ~5 µL of sample in a small eppitube and store at -80°C.  This sample will be 
used for mRNA purity analysis on the Agilent 2100 Bioanalyzer. 
5. Add 0.1 volume (~5 µL) 0.1 mM EDTA in DEPC treated water (Applied 
Biosystems, AM9912). Store at -80°C.  
 
SUPPLIES and REAGENTS: 
Applied Biosystems 
ToTally RNA Kit   AM1910 
Nuclease Free Water  AM9937 
0.1 EDTA in DEPC treated water AM9912 
Denaturation Solution  AM8540G  
 
Quantifying mRNA in samples 
 
1. Turn on computer and NanoDrop 1000 spectrophotometer (ThermoScientific, 
Wilmington, DE).  Verify that NanoDrop 1000 is plugged in properly to the 
computer. 
2. Open ND-1000 software. Select “Nucleic Acid.” 
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3. Lift the sample arm. Put ddH2O on a KimWipe, then use the moistened KimWipe to 
clean the upper and lower pedestals. 
4. Load 1 µL of ddH2O on the lower pedestal, lower the sample arm, and click OK. 
This will calibrate the spectrophotometer. 
5. Clean the pedestals as described in # 3. 
6. Change Sample Type to “RNA-40.” 
7. Load 1 µL of ddH2O and click “BLANK.” This will calibrate the spectrophotometer 
again. 
8. Clean the pedestals as in # 3. 
9. Type sample name in “Sample ID” field. Load 1 µL of sample on the lower pedestal 
and lower the sample arm.  Click “Measure.” 
10. Allow the run to complete and the curve for the sample to appear. Clean the pedestals 
as in # 3. 
11. Repeat Steps 9 and 10 for all samples, making sure the pedestals are cleaned before 
each run. 
12. Load 1 µL of ddH2O and click “BLANK.”  
13. Click “Show Report.” 
a. Concentrations are reported as ng/µL 
b. Purity can be estimated using the 260/280 ratio (should be ~2.0) 
c. Observing the 260/280 ratio and the curves could show potential contaminants.  
Questionable samples should be re-run before sending samples to be analyzed for 
purity using the Nano Chip. 
 
Measuring purity of mRNA 
 
1. Put ~5 µL of each sample in a labeled eppitube. 
2. Place samples in a piggyback rack and place on ice.  Deliver samples to Evelyn in 
Dr. Chapkin’s lab. 
3. Evelyn will run the samples on a NanoChip on an Agilent 2100 Bioanalyzer using 
complementary software. 
a. Make sure Bioanalyzer is connected to computer and power source. 
b. Turn on Bioanalyzer, make sure indicator light is green. 
c. Start Agilent 2100 Bioanalyzer software. 
d. Select Assay>RNA>mRNA nano 
e. Prepare samples, buffer, and nano chip. (See RNA 6000 Nano LabChip kit) 
f. Place chip in Bioanalyzer and close lid. 
g. Click “Start” above the chip icon. 
h. Ensure that sample names are all entered in the “Sample Information” tab. 
i. Change File Prefix and click “Start.” 
j. When the run is finished, clean as indicated by the See RNA 6000 Nano LabChip 
kit. 
k. Print Data. 
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i. RNA Integrity Number (RIN) 
>9 is optimal 
>8 is acceptable, if no errors are seen on the curve 
 
 
NOTES: 
• Prepare and run chips within 10 minutes. Longer chip preparation times may lead to 
evaporation of buffers and to bad chip performance.  
 
• Vortex chips for appropriate 1 minute (not required for protein chips). Improper 
vortexing can lead to poor results. 
 
• Do not force the chip into the receptacle of the Agilent 2100 Bioanalyzer. Proper 
placement of the chip should not require force. Improper placement of the chip could 
damage the electrode assembly when you close the lid. Check whether the chip selector 
is in the correct position. 
 
• Do not touch wells of the chip. The chip could become contaminated, leading to poor 
measurement results. 
 
• Do not leave any wells of the chip empty or the assay will not run properly. Add 1 µL 
of sample buffer to each unused sample well. 
 
 
Creating cDNA 
Invitrogen Superscript™ III Reverse Transcriptase (18080-400, Invitrogen) 
 
1. Get ice, two 2 mL tubes, PCR plate 
2. Add the following components to an RNase free 2 mL tube, label “RT1.”  
a. Hexamers 
b. Oligo dT 
c. Annealing Buffer 
For 48 reactions: 
RT1 Kit amount (mL) # animals (over estimate) Master amount 
(µL) 
Hexamers 0.25 55 13.75 
Oligo dT 1 55 55 
Annealing Buffer 1 55 55 
Total   123.75 
3. Mix well by flicking/vortexing and put RT1 on ice. 
4. Label each microcentrifuge tube with Sample Name, Date, and cDNA. 
5. To each sample well, add 
a. 2.25 µL from RT1 
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b. 700 ng mRNA 
(700ng)/(ng/µL from NanoDrop)= X µL of mRNA sample 
c. Bring volume up to 8 µL/well with nuclease free H2O 
8 µL – 2.25 µL RT1 – X µL mRNA= µL nuclease free H2O 
6. Seal the card, making sure all edges are sealed 
 
7. Centrifuge CR422 (Program 11: 184 mm radius) 
a. 1.5 min at 4°C 
b. 1,000 rpm 
8. Turn on thermocycler and load program “LER1.” Make sure it is set for 96 well 
plate. 
a. Heat mixture to 65°C for 5 min  
9. Incubate on ice for at least 1 min. 
10. While heating/incubating on ice, prepare RT2.  Label tube “RT2” and add the 
following: 
a. 2X buffer 
b. SSIII RT/RNase block 
For 48 animals: 
RT2 Kit amount (mL) # animals (over estimate) Master amount (µL) 
2X Buffer 10 55 550 
SSIII RT/RNase 
block 
2 55 110 
Total   660 
11. To each sample, add 12 µL of RT2 
12. Seal the card and centrifuge (Program 11: 184 mm radius) 
a. 1.5 min at 4°C 
b. 1,000 rpm 
13. Load program “LER2” on the thermocycler. 
a. 25°C for 10 min 
b. 50°C for 50 min 
c. 85°C for 5 min (inactivate reaction) 
*Verify purity/concentrations of cDNA by using Quantifying mRNA in samples protocol 
on page 80, except set “Sample Type” to DNA (default). 
 
TaqMan Microfluidic Array Cards 
TaqMan® Custom Arrays (434229, Applied Biosystems) 
 
1. Get ice and cold plate. 
2. Place PCR plate on cold plate. 
3. Record which samples are in each well. 
4. Add the following to each well 
a. 20X Primer/Probe mix 
b. 2X TaqMan Universal Master Mix, No AmpErase UNG (4324018, 
Applied Biosystems) 
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c. RNase free water 
d. cDNA 
 
 
 1 reaction # animals (over estimate) Master amount (µL) 
20X Primer/Probe 
mix 
1 55 55 
2X TaqMan 
Universal Master 
Mix 
10 55 550 
RNase free water 8 55 440 
Total   1,045 
5. Add 19 µL of Master Mix made in #4 to each well 
6. Add 1 µL of cDNA to each well, keeping track of which sample goes into which 
well.  
7. Remove TaqMan Microfluidic Array Card (4342249, Applied Biosystems) from 
the refrigerator and remove from packaging. 
8. Load 20 µL of sample into each well.  Pipette slowly to allow air to exit the well 
and to avoid bubbles. 
9. Wrap loaded cards in foil and place on ice.  Take cards upstairs to Dr. Chapkin’s 
lab and centrifuge (1,200 rpm, 2 min)  
10. Seal the card. 
a. Position the sealer/carriage 
b. Insert card into sealer, foil side up and snap into place 
c. Push the carriage across the sealer in the direction of the arrows **DO 
NOT MOVE THE CARRIAGE BACK BEFORE REMOVING THE 
TAQMAN ARRAY 
d. Remove the card and return the carriage to starting position 
11. Use scissors to trim off the fill reservoirs 
12. Re-wrap in foil and store at 4°C until further analysis.  Cards should be run 
within 4-8 h of preparation. 
13. Turn on 7900HT and the computer, and open SDS 2.4 software. 
a. The TaqMan Array Microfluidid Card Thermocycling Block must be 
installed 
14. File>New 
a. Assay= ΔΔCT (RQ) 
b. Container=384 Wells TaqMan Low Density Array 
c. Click OK 
15. File>Import 
a. *Use the CD provided with the custom TaqMan Array  
b. Navigate to the SDS Setup File 
c. Click Import 
16. Save the SDS Plate document 
a. File>Save As 
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b. .sds or .sdt 
c. Click Save 
17. Open the SDS plate document, if not already open 
18. Select the Instrument tab 
Default thermocycling conditions have been loaded from the CD 
19. Select the Real-Time tab 
a. Click “Connect to Instrument” 
b. Click “Open/Close” 
c. Remove card from foil and place card in the card holder, barcode facing 
toward you 
d. Click “Open/Close” 
e. Click “Run” 
20. To remove card once the run is complete, click “Open/Close” 
21. Disconnect the instrument from the computer.  Save data in SDS file on flash 
drive. Shut down all equipment. 
 
Analyzing mRNA expression data 
1. Open SDS 2.4 
a. Load SDS files 
b. View amplification plots for each gene 
i. Verify smooth curves and when it crosses the threshold 
c. View errors for each animal and gene 
i. View Troubleshooting help page to determine which errors merit 
exclusion of the data 
2. Open RQ Manager 1.2.2 
3. File>New Study 
a. Load all SDS files 
b. Select all animals, including their duplicate runs 
c. Select 18S as the Endogenous Control Detector 
d. Click Analyze 
4. Export data to excel and calculate gene expression (2(40-CT)) 
 
Measuring SCFA concentrations in the fecal material 
 
1. Powder the samples 
a.  grind in a chilled (liquid nitrogen) mortar and pestle   
2. Powdered samples were weighed (~0.30 g) and mixed with 1 mL internal standard 
solution (2-ethylbutyric acid in 70% ethanol) 
3. Vortex and incubated overnight at 4°C.  To isolate SCFA,  
4. Vortex again, then centrifuge at 15,000 rcf for 30 m at 4°C   
5. Remove the supernatant 
a. To 100 µL supernatant, add 100 µL 70% ethanol (excess supernatant stored at 
-20°C) 
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b. Add 200 µL internal standard solution (heptanoic acid in 70% ethanol)  
c. Right before analysis, add 20 µL H3PO4  
6. Turn on GC  
Varian 3900 GC fitted with an HP-FFAP 30 m, 0.53 mm i.d. capillary column 
(Agilent, CA). 1 m of deactivated glass capillary precolumn (Supelco, Bellmonte, 
PA) was in place as a guard column. 
7. Turn on the computer 
a. Ensure there are no error in communication between Varian CP3841 
Autoinjector, the GC, and the computer 
8. Load Program (STFRT) and place samples into the Auto Injector.  Label Sample 
names appropriately (be sure to change the vial number for each sample) 
a. At the beginning of each run and after every 4 samples, place a vial 
containing 70% EtOH 
b. Ensure that wash vials are full and the caps are intact  
c. The GC conditions were programmed as follows: injector temperature, 
200°C; detector temperature, 300°C; column ﬂow, 7.0 mL/min He; make-up 
ﬂow, 23 mL/min nitrogen. Oven temperature increased from 60°C to 220°C 
by a triple gradient over 51 min.   
9. 1 µL was then injected  
10. Data were integrated and plotted using the Varian Start Workstation Program 
(Agilent) 
11. Fecal production and moisture content data will be used to calculate SCFA 
concentrations on a dry weight basis and 24-h SCFA excretion.  
 
 
 
 
 
  
% dry matter= g dry wt/ g wet wt * 100% 
 
µmol SCFA  x g wet wt = µmol SCFA 
 g wet wt         g dry wt        g dry wt 
 
average g feces (stale) x % dry matter (stale) = g fecal production (dry wt)/ 24 h 
              24 h 
µmol SCFA  x g fecal production (dry wt) = µmol SCFA 
 g dry wt                          24 h                             24 h 
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Coomassie Protein Assay 
 
 
Reagents 
Coomassie Plus Protein Assay Kit (23236, Pierce, Rockford, IL)  
contains:  Coomassie Plus (Bradford) Assay Reagent,  
Albumin (BSA) Standard Ampules (2 mg/ml)  
 
Procedure:  
 
1. Prepare BSA standards:  
  
Vial Volume of dH20 Volume/Source of BSA Final BSA 
Concentration 
A 3,555 µL 45 µL of Stock 25 µg/mL 
B 6,435 µL 65 µL of Stock 20 µg/mL 
C 3,970 µL 30 µL of Stock 15 µg/mL 
D 3,000 µL 3,000 µL of vial B dilution 10 µg/mL 
E 2,500 µL 2,500 µL of vial D dilution 5 µg/mL 
F 1,700 µL 1,700 µL of vial E dilution 2.5 µg/mL 
 
2. Prepare samples, buffer and standards in 1:800 dilutions in a 2 mL eppitube. 
 
*The sample buffer was used from the particular set (during kills).  In the case of more 
than one set run per plate, the buffer was divided into equal portions and added to the 
blank or standard. 
 
3. Pipette 150 µL standard, sample, and blank into each appropriate well.  The standards, 
blank, and samples were run in triplicate. 
 
4. Add 150 µL Coomassie Plus Reagent to each well and mix with plate shaker for 30 s. 
 
5. Incubate samples at RT for 10 minutes.  
 
6. Measure absorbance (A595) on plate reader.  
 
7. Subtract the mean blank reading from each of the sample and standard replicates to 
find their means. 
 
Type Sample Source µL of Sample Source µL of diluent 
Standards A-F Sample buffer* 0.625 499.375 of BSA standards 
Sample Mucosa sample 0.625 499.375 of dH2O 
Blank Sample buffer* 0.625 499.375 of dH2O 
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TransAM NF-κB p65 (101016, Active Motif, Carlsbad, CA) 
 
1. Prepare buffers for appropriate number of wells 
Buffer Reagent 1 well 
Complete Lysis Buffer DTT 0.11 µL 
 Protease Inhibitor 0.23 µL 
 Lysis Buffer AM2 22.2 µL 
  22.5 µL total 
   
Complete Binding Buffer DTT 0.07 µL 
 Herring sperm DNA 0.34 µL 
 Binding buffer AM3 33.4 µL 
  33.8 µL total 
   
1x Wash Buffer Distilled Water 2.025 mL 
 10x wash buffer AM2 225 µL 
  2.25 mL total 
   
1x Antibody binding buffer Distilled water 157.5 µL 
 10x Ab Binding Buffer AM2 17.5 µL 
  175 µL total 
   
Chemiluminescent 
Working Solution 
Chemi Reagent 18.8 µL 
 Reaction Buffer 37.5 µL 
  56.2 µL total 
 
2. Add 30 µL Complete Binding Buffer to each well to be used.  (We did not complete 
the competitive binding step) 
 
3. Sample Wells: Add 20 µL of sample diluted in Complete Lysis Buffer (4 µg of 
protein/sample) 
Positive control Well: Add 1.25 µg of the provided Jurkat nuclear extract diluted in 20 
µL of Complete Lysis Buffer (0.5 µg of nuclear extract in 19.5 µL of Complete Lysis 
Buffer) 
Blank Well: Add 20 µL of Complete Lysis Buffer per well. 
Blank and Buffer Well: Add 0.33 µL of set A buffer with 19.67 µL of Complete Lysis 
Buffer for a total of 20 µL. 
 
4. Cover and incubate for 1 h at RT with mild agitation. 
 
5. Wash each well 3 times with 200 µL 1x wash buffer. 
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6. Add 50 µL of diluted NF-κB antibody (1:10,000 dilution in 1x antibody binding 
buffer) to each well. 
 
7. Incubate for 1 h without agitation at RT. Repeat wash steps. 
 
8. Add 50 µL of diluted HRP-conjugated antibody (1:10,000 dilution in 1x antibody 
binding buffer) to each well. 
 
9. Incubate for 1 h without agitation.  Place working solution at RT.  Wash 4 times with 
1X wash buffer. 
 
10. Add 50 µL RT working solution to all wells. Minimize exposure to light. 
 
11. Read luminescence in plate reader.  For best results, read at several different 
sensitivities. The results for this assay were read at 180 sensitivity. 
 
12. Subtract the “blank and buffer” reading from all of the wells. 
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APPENDIX B 
 
TABLES OF RESULTS 
 
Body weight over time 
 
 
TABLE B-1 Body weight (g) measured throughout the study1 
Appx.
Day 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control       DSS Control DSS Control DSS 
0 65.9±2.6 67.1±2.5 65.1±2.6 65.5±2.5 65.7±2.6 66.9±2.5 
18 170.1±4.4 174.3±4.2 167.8±4.4 172.8±4.2 169.0±4.4 172.8±4.2 
22 189.6±4.8 193.7±4.6 189.3±4.8 194.3±4.6 190.6±4.8 192.2±4.6 
36 264.9±6.1 265.0±5.8 260.5±6.1 268.6±5.8 264.7±6.1 264.6±5.8 
43 281.8±6.4 272.8±6.1 271.2±6.4 278.0±6.1 279.0±6.4 270.9±6.1 
50 315.3±7.8 308.5±7.4 308.4±7.8 323.2±7.4 311.1±7.8 313.4±7.4 
60 340.3±8.5 333.1±8.1 322.0±8.5 342.1±8.1 335.5±8.5 340.2±8.1 
64 345.8±9.2 335.6±8.8 333.4±9.2 346.6±8.8 339.8±9.2 346.4±8.8 
1 Values are LS means ± SEM. No significant differences were observed. n=10-11 rats/group. 
 
Fecal moisture content over time 
 
 
TABLE B-2 Fecal moisture content [(g dry matter/g wet weight)*100%] over time on 
fresh samples1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 48.3±1.0ab 48.6±1.0ab 48.8±1.0ab 50.4±0.9b 47.0±1.0a 48.6±1.0ab 
Post DSS1 49.1±1.5a 66.1±1.5b 50.4±1.5a 64.5±1.5b 48.1±1.6a 69.2±1.5b 
Pre DSS 2 49.6±1.3ab 57.0±1.2c 51.1±1.3b 57.3±1.3c 46.9±1.4a 57.5±1.3c 
Post DSS2 48.1±1.8a 62.1±1.8b 52.4±1.8a 63.5±1.8bc 47.6±1.8a 68.5±1.8c 
Pre DSS3 50.5±1.6b 56.7±1.6c 49.6±1.6ab 57.3±1.5c 45.9±1.6a 58.4±1.5c 
Post DSS3 47.2±1.7a 67.5±1.6b 48.6±1.7a 64.3±1.5b 47.0±1.6a 66.2±1.6b 
Pre-Kill 50.8±1.9a 56.6±1.7b 49.8±1.9a 58.8±1.8b 47.3±2.0a 59.4±1.7b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
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SCFA Concentrations on wet weight basis 
 
 
TABLE B-3 Acetic acid concentrations (µmol/g wet weight feces) on wet weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 12.9±0.8a 13.7±0.8a 12.7±0.8a 13.0±0.8a 13.2±0.8a 17.6±0.8b 
Post DSS1 16.2±1.4ab 21.4±1.4c 13.7±1.4a 17.2±1.4a 13.2±1.4a 18.4±1.4bc 
Pre DSS3 12.5±1.2a 18.2±1.2b 12.1±1.2a 16.1±1.2b 11.9±1.2a 22.7±1.2c 
Post DSS3 13.0±1.3a 21.4±1.2c 11.6±1.3a 17.8±1.2b 12.3±1.3a 23.8±1.2c 
Pre-Kill 11.6±1.1a 15.8±1.1b 12.7±1.1a 18.4±1.1b 10.6±1.1a 18.0±1.1b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=10-11 rats/group. 
 
 
TABLE B-4 Propionic acid concentrations (µmol/g wet weight feces) on wet weight 
basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 4.5±0.4a 4.5±0.4a 4.3±0.4a 4.7±0.4a 4.6±0.4a 5.4±0.4a 
Post DSS1 5.0±0.4ab 6.1±0.4b 4.8±0.4a 5.0±0.4ab 4.9±0.4a 5.4±0.4ab 
Pre DSS3 3.1±0.6a 6.0±0.5b 3.5±0.6a 5.4±0.5b 3.6±0.6a 6.7±0.5b 
Post DSS3 3.6±0.4a 5.5±0.4b 2.7±0.4a 5.3±0.4b 3.0±0.4a 6.4±0.4b 
Pre-Kill 2.9±0.5a 5.5±0.4b 3.3±0.5a 5.4±0.4b 2.4±0.5a 6.0±0.4b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=10-11 rats/group. 
 
 
TABLE B-5 Isobutyric acid concentrations (µmol/g wet weight feces) on wet weight 
basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 0.86±0.1ab 0.87±0.1ab 0.77±0.1a 0.86±0.1ab 1.0±0.1b 0.93±0.1ab 
Post DSS1 0.94±0.1cd 0.72±0.1ab 0.82±0.1bc 0.64±0.1a 1.1±0.1d 0.61±0.1a 
Pre DSS3 0.81±0.1ab 0.85±0.1ab 0.75±0.1a 0.82±0.1ab 0.85±0.1ab 0.93±0.1b 
Post DSS3 0.77±0.04bc 0.73±0.04b 0.74±0.04b 0.59±0.04a 0.88±0.04c 0.71±0.04ab 
Pre-Kill 0.75±0.05ab 0.85±0.05bc 0.70±0.05a 0.92±0.05c 0.76±0.05ab 0.88±0.05bc 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=10-11 rats/group. 
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TABLE B-6 Butyric acid concentrations (µmol/g wet weight feces) on wet weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 5.0±0.4ab 4.9±0.4a 5.2±0.4ab 5.5±0.4ab 5.9±0.4b 5.9±0.4b 
Post DSS1 5.5±0.5a 6.8±0.5b 5.8±0.5ab 5.7±0.5ab 5.8±0.5ab 6.1±0.5ab 
Pre DSS3 4.8±0.4ab 5.3±0.4b 5.1±0.4ab 4.8±0.4ab 4.3±0.4a 6.5±0.1c 
Post DSS3 4.2±0.4a 5.1±0.3a 4.5±0.4a 4.7±0.3a 4.4±0.4a 4.9±0.3a 
Pre-Kill 3.9±0.3a 4.5±0.3ab 4.8±0.3b 5.3±0.3b 3.9±0.3a 4.4±0.3ab 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=10-11 rats/group. 
 
 
TABLE B-7 Isovaleric acid concentrations (µmol/g wet weight feces) on wet weight 
basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 2.1±0.2ab 2.1±0.2ab 1.8±0.2a 2.0±0.2ab 2.5±0.2b 2.2±0.4ab 
Post DSS1 2.2±0.1bc 1.4±0.1a 1.9±0.2b 1.2±0.1a 2.6±0.2c 1.2±0.1a 
Pre DSS3 1.9±0.1ab 1.8±0.1ab 1.7±0.1a 1.7±0.1a 2.1±0.1b 1.9±0.1ab 
Post DSS3 1.8±0.1a 1.3±0.1b 1.7±0.1a 1.1±0.1b 2.1±0.1a 1.2±0.1b 
Pre-Kill 1.7±0.1a 1.7±0.1a 1.6±0.1a 1.8±0.1a 1.8±0.1a 1.7±0.1a 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=10-11 rats/group. 
 
 
TABLE B-8 Valeric acid concentrations (µmol/g wet weight feces) on wet weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 1.9±0.1a 1.8±0.1a 1.8±0.1a 1.8±0.1a 2.2±0.1b 2.0±0.1ab 
Post DSS1 1.9±0.1bc 1.6±0.1ab 1.8±0.1b 1.3±0.1a 2.1±0.1c 1.4±0.1a 
Pre DSS3 1.6±0.1a 1.8±0.1ab 1.6±0.1a 1.7±0.1a 1.7±0.1a 2.0±0.1b 
Post DSS3 1.6±0.1a 1.5±0.1a 1.5±0.1a 1.2±0.1b 1.6±0.1a 1.5±0.1a 
Pre-Kill 1.4±0.1a 1.6±0.1ab 1.4±0.1a 1.7±0.1b 1.6±0.1ab 1.7±0.1b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=10-11 rats/group. 
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TABLE B-9 Total SCFA concentrations (µmol/g wet weight feces) on wet weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 27.3±1.4a 27.9±1.3a 26.6±1.4a 27.8±1.3a 29.3±1.4a 34.0±1.3b 
Post DSS1 31.7±1.9a 38.0±1.8b 28.8±1.9a 31.2±1.8a 29.7±1.9a 33.2±1.8ab 
Pre DSS3 24.6±2.1a 33.9±2.0c 24.7±2.1ab 30.5±2.0bc 24.4±2.1a 40.7±2.0d 
Post DSS3 25.0±1.7a 35.5±1.7c 22.8±1.7a 30.6±1.7b 24.2±1.7a 38.5±1.7c 
Pre-Kill 22.2±1.7a 30.0±1.7b 24.5±1.7a 33.5±1.7b 21.1±1.7a 32.8±1.7b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=10-11 rats/group. 
 
 
Concentrations on dry weight basis 
 
 
TABLE B-10 Acetic concentrations (µmol/g dry weight feces) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 25.0±1.5a 26.4±1.5a 25.7±1.5a 26.4±1.4a 24.7±1.5a 32.6±1.5b 
Post DSS1 31.7±5.5a 65.8±5.5c 28.2±5.5a 49.7±5.5b 25.2±5.5a 65.9±5.5c 
Pre DSS3 25.7±3.9a 46.0±3.9bc 24.1±3.9a 37.9±3.7b 22.2±4.1a 55.5±3.7c 
Post DSS3 24.9±5.1a 73.4±4.8c 22.4±5.1a 53.4±4.6b 23.3±4.8a 74.0±4.8c 
Pre-Kill 23.2±3.6a 38.5±3.2b 24.7±3.6a 45.5±3.4b 20.9±3.8a 45.4±3.2b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-11 Propionic concentrations (µmol/g dry weight feces) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 8.9±0.8ab 8.7±0.9ab 7.8±0.9a 9.5±0.8ab 8.5±0.9ab 10.3±0.8b 
Post DSS1 9.9±1.0a 17.9±1.0c 10.0±1.0a 14.3±1.0b 9.6±1.0a 17.9±1.0c 
Pre DSS3 6.4±1.6a 15.5±1.6b 6.9±1.6a 12.9±1.6b 6.9±1.7a 16.3±1.6b 
Post DSS3 6.5±1.2a 18.4±1.1c 5.4±1.2a 15.2±1.1b 5.7±1.1a 19.2±1.1c 
Pre-Kill 5.5±1.6a 13.3±1.4b 6.4±1.6a 13.1±1.5b 4.9±1.7a 15.3±1.4b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
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TABLE B-12 Isobutyric concentrations (µmol/g dry weight feces) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 1.7±0.1a 1.6±0.1a 1.6±0.1a 1.8±0.1a 1.9±0.1a 1.8±0.1a 
Post DSS1 1.8±0.1a 2.1±0.1a 1.7±0.1a 1.8±0.1a 2.0±0.2a 2.0±0.1a 
Pre DSS3 1.7±0.2ab 2.1±0.2b 1.5±0.2a 1.9±0.2abc 1.6±0.2a 2.3±0.2c 
Post DSS3 1.4±0.1a 2.2±0.1b 1.5±0.1a 1.7±0.1a 1.7±0.1a 2.1±0.1b 
Pre-Kill 1.5±0.2a 2.0±0.1b 1.4±0.2a 2.3±0.2b 1.6±0.2a 2.2±0.1b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-13 Butyric concentrations (µmol/g dry weight feces) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 9.7±0.8a 9.6±0.9a 10.9±0.9a 11.1±0.8a 11.3±0.8a 11.5±0.8a 
Post DSS1 10.7±1.7a 21.1±1.7c 11.8±1.7ab 16.5±1.7bc 10.9±1.8a 20.9±1.7c 
Pre DSS3 9.7±1.0ab 13.1±1.0cd 10.1±1.0a 11.3±1.0bc 7.9±1.0a 15.8±1.0d 
Post DSS3 7.9±1.7a 17.7±1.6b 8.9±1.7a 13.9±1.5b 8.3±1.6a 15.1±1.6b 
Pre-Kill 8.0±0.9a 10.8±0.8bc 9.6±0.9ab 13.1±0.8c 8.0±0.9a 11.0±0.8bc 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-14 Isovaleric concentrations (µmol/g dry weight feces) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 4.1±0.3a 3.9±0.3a 3.8±0.3a 4.1±0.3a 4.7±0.3a 4.4±0.3a 
Post DSS1 4.3±0.3a 4.0±0.3a 3.9±0.3a 3.5±0.3a 4.9±0.3a 3.9±0.3a 
Pre DSS3 3.8±0.3ab 4.3±0.3ab 3.5±0.3a 4.1±0.3ab 3.9±0.3ab 4.7±0.3b 
Post DSS3 3.4±0.2ab 3.8±0.2b 3.4±0.2ab 3.1±0.2a 3.9±0.2b 3.3±0.2ab 
Pre-Kill 3.5±0.3ab 4.1±0.3abc 3.2±0.3a 4.4±0.3bc 3.7±0.3abc 4.4±0.3c 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
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TABLE B-15 Valeric concentrations (µmol/g dry weight feces) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 3.6±0.2a 3.4±0.2a 3.6±0.2a 3.7±0.2a 4.2±0.2a 4.0±0.2a 
Post DSS1 3.7±0.3ab 4.8±0.3d 3.6±0.3a 3.8±0.3bc 4.0±0.3abcd 4.7±0.3cd 
Pre DSS3 3.3±0.3a 4.4±0.3bc 3.2±0.3a 3.9±0.3ab 3.2±0.3a 5.0±0.3c 
Post DSS3 2.9±0.3a 4.9±0.3b 3.0±0.3a 3.5±0.2a 3.1±0.3a 4.3±0.3b 
Pre-Kill 3.0±0.3a 3.9±0.3b 3.0±0.3a 4.3±0.3b 3.1±0.3a 4.3±0.3b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-16 Total SCFA concentrations (µmol/g dry weight feces) on dry weight 
basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 53.1±2.7a 53.6±2.9a 53.6±2.9a 56.6±2.6a 55.2±2.9a 64.6±2.7b 
Post DSS1 62.1±7.6a 115.6±7.6c 59.1±7.6a 89.7±7.6b 56.6±8.0a 115.2±7.6c 
Pre DSS3 50.7±6.7a 85.4±6.7bc 49.4±6.7a 72.0±6.4b 45.7±7.1a 99.4±6.4c 
Post DSS3 47.1±7.7a 120.4±7.3c 44.5±7.7a 90.8±6.9b 45.8±7.3a 118.1±7.3c 
Pre-Kill 44.7±6.1a 72.7±5.5b 48.3±6.1a 82.6±5.8b 42.2±6.5a 82.7±5.5b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
24 h SCFA concentrations 
 
 
TABLE B-17 24 h production of acetic acid (µmol/d) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 10.4±1.1 12.6±1.2a 12.4±1.2a 11.5±1.0a 10.0±1.2a 12.7±1.1a 
Post DSS1 14.4±5.1a 47.3±4.8b 15.2±4.8a 42.8±5.4b 11.7±5.1a 49.5±4.8b 
Pre DSS3 15.2±3.5a 33.5±3.5b 13.7±3.3a 20.3±3.1a 11.0±3.5a 34.6±3.3b 
Post DSS3 12.5±8.7a 64.5±7.7b 10.7±8.2a 49.3±7.4b 10.5±7.7a 61.5±8.1b 
Pre-Kill 12.6±3.4a 22.6±3.2b 12.4±3.4a 31.1±3.2b 10.7±3.6a 27.6±3.2b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
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TABLE B-18 24 h production of propionic acid (µmol/d) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 3.6±0.5a 4.1±0.5a 3.7±0.5a 4.2±0.4a 3.4±0.5a 4.0±0.5a 
Post DSS1 4.3±1.5a 13.3±1.4b 5.4±1.4a 11.4±1.5b 4.5±1.5a 14.1±1.4b 
Pre DSS3 3.4±1.3a 11.4±1.3c 3.9±1.3a 6.9±1.2a 3.3±1.3a 10.3±1.3b 
Post DSS3 3.0±2.2a 16.5±2.0b 2.6±2.1a 13.5±1.9b 2.7±2.0a 15.8±2.1a 
Pre-Kill 3.1±1.1a 8.3±1.1b 3.3±1.2a 8.8±1.1b 2.5±1.2a 9.1±1.1b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-19 24 h production of isobutyric acid (µmol/d) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 0.68±0.1a 0.76±0.1a 0.78±0.1a 0.78±0.1a 0.77±0.1a 0.73±0.1a 
Post DSS1 0.82±0.2a 1.47±0.1b 0.88±0.1a 0.51±0.2b 0.90±0.1a 1.57±0.2b 
Pre DSS3 0.94±0.2a 1.5±0.2c 0.87±0.1a 1.0±0.1ab 0.80±0.2a 1.4±0.1bc 
Post DSS3 0.76±0.2a 1.9±0.2b 0.68±0.2a 1.5±0.2b 0.76±0.2a 1.7±0.2b 
Pre-Kill 0.83±0.2ab 1.2±0.1bc 0.70±0.2a 1.5±0.1c 0.81±0.2ab 1.3±0.1c 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05). n=8-11 
rats/group. 
 
 
TABLE B-20 24 h production of butyric acid (µmol/d) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 4.0±0.4a 4.5±0.4a 5.2±0.4a 4.6±0.4a 4.6±0.4a 4.5±0.4a 
Post DSS1 4.8±1.9a 15.0±1.8b 6.2±1.8a 14.0±2.0b 4.8±1.9a 16.7±1.8b 
Pre DSS3 5.7±1.0a 9.5±1.0b 5.8±1.0a 6.2±1.0a 3.4±1.0a 9.4±1.0b 
Post DSS3 4.1±2.9ab 16.7±2.6c 4.3±2.8ab 12.7±2.5c 2.8±2.6a 11.8±2.8bc 
Pre-Kill 4.4±0.9ab 6.6±0.8abc 4.9±0.9ab 8.8±0.8c 4.1±0.9a 6.7±0.8bc 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05). n=8-11 
rats/group. 
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TABLE B-21 24 h production of isovaleric acid (µmol/d) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 1.7±0.2a 1.9±0.2a 1.8±0.2a 1.9±0.2a 1.9±0.2a 1.7±0.2a 
Post DSS1 1.9±0.3a 2.8±0.3b 2.0±0.3ab 2.8±0.3c 2.2±0.3abc 3.0±0.3c 
Pre DSS3 2.2±0.3ab 3.1±0.3b 2.0±0.3a 2.2±0.3ab 2.0±0.3a 2.8±0.3ab 
Post DSS3 1.8±0.3ab 3.1±0.3c 1.6±0.3a 2.6±0.3bc 1.8±0.3a 2.8±0.3c 
Pre-Kill 1.9±0.3ab 2.4±0.3b 1.6±0.3a 2.9±0.3c 1.9±0.3ab 2.5±0.3bc 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-22 24 h production of valeric acid (µmol/d) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 1.5±0.2a 1.6±0.2a 1.7±0.2a 1.6±0.2a 1.7±0.1a 1.6±0.1a 
Post DSS1 1.6±0.3a 3.4±0.3b 1.9±0.3a 3.1±0.3b 1.8±0.3a 3.6±0.3b 
Pre DSS3 1.9±0.3a 3.1±0.3b 1.8±0.3a 2.1±0.3a 1.6±0.3a 3.0±0.3b 
Post DSS3 1.5±0.5a 4.2±0.5b 1.4±0.5a 3.1±0.4b 1.4±0.5a 3.5±0.5b 
Pre-Kill 1.6±0.3ab 2.4±0.3bc 1.5±0.3a 2.9±0.3d 1.6±0.3ab 2.6±0.3cd 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-23 24 h production of total SCFA (µmol/d) on dry weight basis1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 21.9±2.1a 25.5±2.2a 25.7±2.2a 24.6±2.0a 22.4±2.2a 25.4±2.1a 
Post DSS1 27.8±8.5a 83.2±8.1b 31.7±8.1a 75.8±9.0b 26.0±8.5a 88.5±8.1b 
Pre DSS3 29.2±6.3a 62.0±6.3b 28.1±6.0a 38.7±5.7a 22.6±6.3a 61.6±6.0b 
Post DSS3 23.7±14.4a 107.0±12.9b 21.2±13.6a 82.8±12.3b 21.0±12.9a 97.1±13.6b 
Pre-Kill 24.5±5.8a 43.4±5.5b 24.4±5.8a 56.0±5.5b 21.6±6.2a 49.8±5.5b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
 
 
 
 99 
 
Relative SCFA Concentrations 
 
 
TABLE B-24 Relative acetic acid concentrations [(µmol acetic acid/µmol total 
SCFA)*100%)1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 47.1±1.4ab 49.4±1.4b 48.0±1.4ab 46.9±1.3ab 45.0±1.4a 50.3±1.4b 
Post DSS1 50.4±1.8bc 55.8±1.8d 47.4±1.8ab 54.7±1.8cd 44.9±1.9a 55.9±1.8d 
Pre DSS3 50.7±1.0ab 53.3±1.0bc 49.0±1.0a 52.8±1.0bc 48.6±1.1a 55.6±1.0c 
Post DSS3 52.3±1.5a 60.7±1.4bc 50.5±1.5a 57.6±1.4b 50.8±1.4a 62.6±1.4c 
Pre-Kill 51.5±1.2ab 52.6±1.1abc 50.5±1.2a 55.1±1.2bc 49.6±1.3a 54.7±1.1c 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-25 Relative propionic acid concentrations [(µmol propionic acid/µmol total 
SCFA)*100%)1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 16.8±1.1a 16.0±1.2a 14.7±1.2a 16.7±1.1a 15.1±1.2a 16.0±1.1a 
Post DSS1 16.0±1.1a 16.1±1.1a 16.7±1.1a 16.4±1.1a 16.6±1.1a 16.4±1.1a 
Pre DSS3 11.8±1.1a 17.5±1.1c 13.9±1.1ab 17.4±1.0c 14.7±1.2abc 16.4±1.0bc 
Post DSS3 13.4±1.0ab 15.5±1.0bc 12.0±1.0a 17.5±1.0c 11.9±1.0a 16.3±1.0c 
Pre-Kill 12.1±0.8a 17.9±0.7b 13.1±0.8a 15.8±0.8b 11.7±0.8a 18.0±0.8b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
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TABLE B-26 Relative isobutyric acid concentrations [(µmol isobutyric acid/µmol total 
SCFA)*100%)1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 3.1±0.2a 3.0±0.2a 3.0±0.2a 3.1±0.2a 3.4±0.2a 2.9±0.2a 
Post DSS1 3.0±0.2bc 1.9±0.2a 2.9±0.2b 2.1±0.2a 3.5±0.2c 1.8±0.2a 
Pre DSS3 3.3±0.2cd 2.6±0.2ab 3.0±0.2bc 2.7±0.2ab 3.6±0.2d 2.3±0.2a 
Post DSS3 3.1±0.2b 1.9±0.2a 3.3±0.2bc 2.0±0.4a 3.7 ±0.2c 1.8±0.2a 
Pre-Kill 3.4±0.2bc 3.0±0.2ab 3.0±0.2ab 2.7±0.2a 3.7±0.2c 2.8±0.2a 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-27 Relative butyric acid concentrations [(µmol butyric acid/µmol total 
SCFA)*100%)1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 18.4±1.0a 17.8±1.1a 20.2±1.1a 19.4±1.0a 20.5±1.1a 17.7±1.0a 
Post DSS1 17.5±0.9a 18.3±0.9ab 20.1±0.9b 18.4±0.9ab 19.4±1.0ab 17.9±0.9ab 
Pre DSS3 19.8±0.8b 15.8±0.8a 20.4±0.8b 15.9±0.8a 17.4±0.8a 15.9±0.8a 
Post DSS3 17.4±1.0bc 14.3±1.0a 19.9±1.0c 15.3±1.0ab 18.2±1.0c 12.8±1.0a 
Pre-Kill 18.2±0.8a 14.9±0.8b 20.2±0.8a 15.9±0.8b 18.9±0.8a 13.7±0.8b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
TABLE B-28 Relative isovaleric acid concentrations [(µmol isovaleric acid/µmol total 
SCFA)*100%)1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 7.7±0.5ab 7.4±0.5ab 7.2±0.5ab 7.3±0.5ab 8.4±0.5b 6.9±0.5a 
Post DSS1 7.1±0.5b 3.6±0.5a 6.6±0.5b 4.1±0.5a 8.6±0.5c 3.4±0.5a 
Pre DSS3 7.7±0.4bc 5.4±0.4a 7.0±0.4b 5.7±0.4a 8.7±0.4c 4.7±0.4a 
Post DSS3 7.4±0.5a 3.4±0.5b 7.6±0.5a 3.6±0.4b 8.6±0.5a 2.9±0.5b 
Pre-Kill 7.9±0.5cd 6.0±0.5ab 6.9±0.5bc 5.3±0.5a 8.8±0.5d 5.5±0.5a 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
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TABLE B-29 Relative valeric acid concentrations [(µmol valeric acid/µmol total 
SCFA)*100%)1 
Time point 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
PreDSS1 6.8±0.3ab 6.4±0.3a 6.8±0.3ab 6.6±0.3a 7.6±0.3b 6.2±0.3a 
Post DSS1 6.0±0.3b 4.2±0.3a 6.3±0.3bc 4.4±0.3a 7.0±0.3c 4.2±0.3a 
Pre DSS3 6.6±0.3a 5.5±0.3b 6.6±0.3a 5.5±0.3b 7.1±0.3a 5.1±0.3b 
Post DSS3 6.3±0.3a 4.2±0.3b 6.8±0.3a 4.0±0.3b 6.8±0.3a 3.7±0.3b 
Pre-Kill 6.8±0.3cd 5.6±0.3ab 6.3±0.3bc 5.2±0.3a 7.4±0.5d 5.3±0.3a 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
 
Post-termination observations 
 
 
TABLE B-30 NF-κB activity (RLU)1 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
12,949±3,359ab 18,707±3,166b 19,444±3,359b 14,781±3,166ab 18,807±3,359ab 10,012±2,864a 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=8-11 rats/group. 
 
TABLE B-31 Injury and Inflammation Scores (0-3)1 
 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
Injury 1.0±0.1b 2.1±0.1c 0.8±0.1ab 2.0±0.1c 0.7±0.1a 2.0±0.1c 
Inflammation 1.0±0.1a 1.7±0.1b 1.0±0.1a 1.6±0.1b 0.8±0.1a 1.6±0.1b 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=9-11 rats/group. 
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TABLE B-32 Gene (mRNA) expression in mucosal scrapings1 
 
Basal Diet Quercetin Diet Chlorogenic Acid Diet 
Control DSS Control DSS Control DSS 
MCT-1 333±26.6b 247±26.6a 352±26.6b 229±26.6a 303±26.6ab 256±26.6a 
SLC5A8 109±9.9b 73.7±9.9a 111±9.9b 83.8±11ab 106±9.9b 101±9.9ab 
FGF-2 98.1±31.9a 182.5±31.9a 139.1±31.9a 306.0±33.1b 172.2±37.3a 175.6±31.9a 
TFF-3 1,334±99bc 1,110±99ab 1,405±99c 969±106a 1,428±99c 1,179±99ac 
TNFR-1 161.0±13.0bc 99.4±13.0a 177.3±13.0c 143.3±13.9bc 147.8±13.0bc 140.1±13.0b 
TNFR-2 6.8±0.9a 7.2±0.9ab 7.6±0.9ab 10.3±1.0c 7.2±0.9ab 9.7±0.9bc 
IκΒα 119±10b 84±10a 125 ±10b 99±11ab 124±10b 108±10ab 
RelA/p65 117±9b 69±9a 107±9b 80±10a 108±9b 80±9a 
RIPk 42.4±3.4ab 34.9±3.4a 47.4±3.4b 35.3±3.6a 42.9±3.4ab 38.5±3.4ab 
IL-12 98±43a 223±45b 176±48ab 425±46c 175±43ab 227±43b 
COX-2 11,189±819c 5,997±793ab 8,113±819b 4,327±848a 8,188±793b 6,512±819ab 
IL-1 1,070±268a 2,264±286b 1,808±268ab 1,488±286ab 1,646±268ab 1,589±268ab 
1 Values are LS means ± SEM. Means with superscripts without a common letter differ (p<0.05).  
n=7-8 rats/group. 
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